232 results on '"Anna Goodman"'
Search Results
2. Clinical management of community-acquired meningitis in adults in the UK and Ireland in 2017: a retrospective cohort study on behalf of the National Infection Trainees Collaborative for Audit and Research (NITCAR)
- Author
-
Amy Robinson, Kamaljit Khalsa, Arjun Chandna, John Bowen, Viva Levee, Jan Coebergh, Tom Solomon, Clive Graham, David Turner, Robert Tilley, Tim Jones, Susan Hopkins, Matthew Stevens, Daniel White, Celestine Eshiwe, Anna Goodman, Ramandeep Singh, Robert S Heyderman, Nicholas Davies, Joseph Thompson, Ed Moran, Sarah Kelly, Martin Williams, Rhea O’Regan, Simon Tiberi, Jonathan Lambourne, Naomi Bulteel, Susan Larkin, Ruth McEwen, Hassan Paraiso, Aarti Shah, Martin Wiselka, Sylviane Defres, Ernest Mutengesa, Maria Krutikov, Ruth Owen, David Griffith, David Harvey, Trupti Patel, Brendan Davies, Emma Mclean, Joanna Allen, Ali Khan, Alastair Miller, Ashutosh Deshpande, Christopher Green, Lewis Jones, Mark Melzer, Fiona McGill, Amanda Fife, Nimal Wickramasinghe, Stephanie Harris, Ewan Hunter, Jayne Ellis, Benedict Rogers, Imogen Fordham, Elen Vink, Victoria Ward, Anna Smith, Andrew Rosser, Alison Muir, Ken Woodhouse, John Shone, Iain Crossingham, Ryan Jayesinghe, Eavan Muldoon, Avneet Shahi, Terry John Evans, Jeremy Wong, Eloisa MacLachlan, Amy Chue, Karishma Gokani, Katherine Ajdukiewicz, Lucinda Barrett, Frances Edwards, Adam Usher, Mairi McLeod, Su su Htwe, Grace Duane, Nicholas Wong, Jennifer Poyner, Jenni Crane, Ollie Lloyd, Emma Chisholm, Ildiko Kustos, Sam Sutton, M. Estee Torok, Isobel Ramsay, Monica Ivan, Joshua York, Jennifer Ansett, Maithili Varadarajan, Priya Sekhon, James Cruise, Shivani Kanabar, Mirella Ling, Charlotte Milne, Jayanta Sarma, Aline Wilson, Lynn Urquhart, Sahar Eldirdiri, Leila White, Jody Aberdein, Phillip Simpson, Hnin Hay Mar, Keying Tan, Eint Shwe Zin thein, Mahmoud Aziz, Anthony Cadwgan, Natasha Weston, Salman Zeb, Angela Houston, Louise Wootton, Iona Willingham, Aimee Johnson, Ashley Horsley, Eamonn Trainor, Olivier Gaillemin, Nicholas J Norton, Katie Cheung, Megan Duxbury, Emilie Bellhouse, Helena Brezovjakova, Kanitkar Tanmay, Alexsander Dawidziuk, Razan Saman, Hugh Adler, Elshadai Ejere, Yiwen Soo, Wendy Beadles, Heather Sturgeon, Brodie Cameron, David Chadwick Ben Tomlinson, Claire McGoldrick, Katie McDowell, Mpho Molosiwa, Katherine FlackAdrian Kennedy, Phoebe Cross, Fay Perry, Vithusha Inpadhas, Sarathy Selvam, Vhairi Bateman, Henry Wu, Monika Pasztor, Ajanthiha Karunakaran, Basma Soliman, Andrew Blanshard, Harish Reddy, Helen Chesterfield, Ben Schroeder, Tee Keat Teoh, Sathyavani Subbarao, Caryn RosmarinLucy Bell, Emma McGuire, Robert Serafino, Ishaan Bhide, Karanjeet Sagoo, Indran Balakrishnan, Kajal Patel, Barzo Faris, Graeme Calver, Ricky Singh, Hazel Sanghvi, Mohamed Eltayeb, and Rathur Haris
- Subjects
Medicine - Abstract
Objectives To assess practice in the care of adults with suspected community-acquired bacterial meningitis in the UK and Ireland.Design Retrospective cohort study.Setting 64 UK and Irish hospitals.Participants 1471 adults with community-acquired meningitis of any aetiology in 2017.Results None of the audit standards, from the 2016 UK Joint Specialists Societies guideline on diagnosis and management of meningitis, were met in all cases. With respect to 20 of 30 assessed standards, clinical management provided for patients was in line with recommendations in less than 50% of cases. 45% of patients had blood cultures taken within an hour of admission, 0.5% had a lumbar puncture within 1 hour, 26% within 8 hours. 28% had bacterial molecular diagnostic tests on cerebrospinal fluid. Median time to first dose of antibiotics was 3.2 hours (IQR 1.3–9.2). 80% received empirical parenteral cephalosporins. 55% ≥60 years and 31% of immunocompromised patients received anti-Listeria antibiotics. 21% received steroids. Of the 1471 patients, 20% had confirmed bacterial meningitis. Among those with bacterial meningitis, pneumococcal aetiology, admission to intensive care and initial Glasgow Coma Scale Score less than 14 were associated with in-hospital mortality (adjusted OR (aOR) 2.08, 95% CI 0.96 to 4.48; aOR 4.28, 95% CI 1.81 to 10.1; aOR 2.90, 95% CI 1.26 to 6.71, respectively). Dexamethasone therapy was weakly associated with a reduction in mortality in both those with proven bacterial meningitis (aOR 0.57, 95% CI 0.28 to 1.17) and with pneumococcal meningitis (aOR 0.47, 95% CI 0.20 to 1.10).Conclusion This study demonstrates that clinical care for patients with meningitis in the UK is not in line with current evidence-based national guidelines. Diagnostics and therapeutics should be targeted for quality improvement strategies. Work should be done to improve the impact of guidelines, understand why they are not followed and, once published, ensure they translate into changed practice.
- Published
- 2022
- Full Text
- View/download PDF
3. Citizen Science Approach to Home Radon Testing, Environmental Health Literacy and Efficacy
- Author
-
Stacy Stanifer, Anna Goodman Hoover, Kathy Rademacher, Mary Kay Rayens, William Haneberg, and Ellen J. Hahn
- Subjects
citizen science ,environmental health ,self-efficacy ,health literacy ,radon ,Science - Abstract
Exposure to radon is a leading cause of lung cancer worldwide. However, few test their homes for radon. There is a need to increase access to radon testing and decrease radon exposure. This longitudinal, mixed-methods study using a citizen science approach recruited and trained a convenience sample of 60 non-scientist homeowners from four rural Kentucky counties to test their homes for radon using a low-cost continuous radon detector, report back findings, and participate in a focus group to assess their testing experience. The aim was to evaluate changes in environmental health literacy (EHL) and efficacy over time. Participants completed online surveys at baseline, post-testing, and 4–5 months later to evaluate EHL, response efficacy, health information efficacy, and self-efficacy related to radon testing and mitigation. Mixed modeling for repeated measures evaluated changes over time. Citizen scientists reported a significant increase in EHL, health information efficacy, and radon testing self-efficacy over time. While there was a significant increase in citizen scientists’ confidence in their perceived ability to contact a radon mitigation professional, there was no change over time in citizen scientists’ beliefs that radon mitigation would reduce the threat of radon exposure, nor was there a change in their capacity to hire a radon mitigation professional. Further research is needed to understand the role of citizen science in home radon mitigation.
- Published
- 2022
- Full Text
- View/download PDF
4. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
- Author
-
Hanna Nguyen, Jo Salkeld, Sangita Agarwal, and Anna Goodman
- Subjects
SARS-CoV2 ,COVID-19 ,Agammaglobulinemia ,REGN-COV2 ,Remdesivir ,Infectious and parasitic diseases ,RC109-216 - Abstract
Background: The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experienced a more protracted disease length. Previous reports have described successful use of convalescent plasma, however there is a paucity of information around the use of the REGN-COV2 antibody cocktail in these patients. Case report: A patient with XLA was admitted to hospital with COVID-19 and remained persistently symptomatic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab positivity despite treatment with Remdesivir and dexamethasone. Attempts at modulating the immune response with anakinra were unsuccessful. Consent for compassionate use of REGN-COV2 was obtained with administration taking place on day 87 of his illness. This was followed by a period of convalescence and SARS-CoV-2 nasopharyngeal swab negativity. As a consequence of prolonged immunosuppression, the patient developed pneumocystis pneumonia. Conclusion: This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged immunosuppression and delayed treatment. We propose that this may be of particular significance given the capacity of SARS-CoV-2 to develop advantageous mutations in a chronically infected host.
- Published
- 2021
- Full Text
- View/download PDF
5. Impacts of 2020 Low Traffic Neighbourhoods in London on Road Traffic Injuries
- Author
-
Anna Goodman, Jamie Furlong, Anthony A. Laverty, Asa Thomas, and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
We assessed the impacts of Low Traffic Neighbourhoods (LTNs) implemented in 2020 on road traffic injuries. We used police data from October-December 2018/2019 (pre) compared with the same period in 2020 (post). We found absolute numbers of injuries inside LTNs halved relative to the rest of London (ratio 0.51, p
- Published
- 2021
- Full Text
- View/download PDF
6. Performance Analysis of the National Early Warning Score and Modified Early Warning Score in the Adaptive COVID-19 Treatment Trial Cohort
- Author
-
Christopher J. Colombo, MD, MA, FACP, FCCM, Rhonda E. Colombo, MD, MHS, FACP, FIDSA, Ryan C. Maves, MD, FCCM, FCCP, FIDSA, Angela R. Branche, MD, Stuart H. Cohen, MD, Marie-Carmelle Elie, MD, Sarah L. George, MD, Hannah J. Jang, PhD, RN, CNL, PHN, Andre C. Kalil, MD, MPH, David A. Lindholm, MD, FACP, Richard A. Mularski, MD, MSHS, MCR, ATSF, FCCP, FACP, Justin R. Ortiz, MD, MS, FACP, FCCP, Victor Tapson, MD, C. Jason Liang, PhD, On behalf of the ACTT-1 Study Group, Aneesh K. Mehta, Nadine G. Rouphael, Jessica J. Traenkner, Valeria D Cantos, Ghina Alaaeddine, Barry S. Zingman, Robert Grossberg, Paul F. Riska, Elizabeth Hohmann, Mariam Torres-Soto, Nikolaus Jilg, Helen Y. Chu, Anna Wald, Margaret Green, Annie Luetkemeyer, Pierre-Cedric B. Crouch, Hannah Jang, Susan Kline, Joanne Billings, Brooke Noren, Diego Lopez de Castilla, Jason W. Van Winkle, Francis X. Riedo, Robert W. Finberg, Jennifer P. Wang, Mireya Wessolossky, Kerry Dierberg, Benjamin Eckhardt, Henry J Neumann, Victor Tapson, Jonathan Grein, Fayyaz Sutterwala, Lanny Hsieh, Alpesh N. Amin, Thomas F. Patterson, Heta Javeri, Trung Vu, Roger Paredes, Lourdes Mateu, Daniel A. Sweeney, Constance A. Benson, Farhana Ali, William R. Short, Pablo Tebas, Jessie Torgersen, Giota Touloumi, Vicky Gioukari, David Chien Lye, Sean WX Ong, Norio Ohmagari, Ayako Mikami, Gerd Fätkenheuer, Jakob J. Malin, Philipp Koehler, Andre C. Kalil, LuAnn Larson, Angela Hewlett, Mark G. Kortepeter, C. Buddy Creech, Isaac Thomsen, Todd W. Rice, Babafemi Taiwo, Karen Krueger, Stuart H. Cohen, George R. Thompson, 3rd, Cameron Wolfe, Emmanuel B. Walter, Maria Frank, Heather Young, Ann R. Falsey, Angela R. Branche, Paul Goepfert, Nathaniel Erdmann, Otto O. Yang, Jenny Ahn, Anna Goodman, Blair Merrick, Richard M. Novak, Andrea Wendrow, Henry Arguinchona, Christa Arguinchona, Sarah L. George, Janice Tennant, Robert L. Atmar, Hana M. El Sahly, Jennifer Whitaker, D. Ashley Price, Christopher J. A. Duncan, Simeon Metallidis, Theofilos Chrysanthidis, F. McLellan, Myoung-don Oh, Wan Beom Park, Eu Suk Kim, Jongtak Jung, Justin R. Ortiz, Karen L. Kotloff, Brian Angus, Jack David Germain Seymour, Noreen A. Hynes, Lauren M. Sauer, Neera Ahuja, Kari Nadeau, Patrick E. H. Jackson, Taison D. Bell, Anastasia Antoniadou, Konstantinos Protopapas, Richard T Davey, Jocelyn D. Voell, Jose Muñoz, Montserrat Roldan, Ioannis Kalomenidis, Spyros G. Zakynthinos, Catharine I. Paules, Fiona McGill, Jane Minton, Nikolaos Koulouris, Zafeiria Barmparessou, Edwin Swiatlo, Kyle Widmer, Nikhil Huprikar, Anuradha Ganesan, Guillermo M. Ruiz-Palacios, Alfredo Ponce de León, Sandra Rajme, Justino Regalado Pineda, José Arturo Martinez-Orozco, Mark Holodniy, Aarthi Chary, Timo Wolf, Christoph Stephan, Jan-Christian Wasmuth, Christoph Boesecke, Martin Llewelyn, Barbara Philips, Christopher J. Colombo, Rhonda E. Colombo, David A. Lindholm, Katrin Mende, Tida Lee, Tahaniyat Lalani, Ryan C. Maves, Gregory C. Utz, Jens Lundgren, Marie Helleberg, Jan Gerstoft, Thomas Benfield, Tomas Jensen, Birgitte Lindegaard, Lothar Weise, Lene Knudsen, Isik Johansen, Lone W Madsen, Lars Østergaard, Nina Stærke, Henrik Nielsen, Timothy H. Burgess, Michelle Green, Mat Makowski, Jennifer L. Ferreira, Michael R. Wierzbicki, Tyler Bonnett, Nikki Gettinger, Theresa Engel, Jing Wang, John H. Beigel, Kay M. Tomashek, Seema Nayak, Lori E. Dodd, Walla Dempsey, Effie Nomicos, Marina Lee, Peter Wolff, Rhonda PikaartTautges, Mohamed Elsafy, Robert Jurao, Hyung Koo, Michael Proschan, Dean Follmann, and H. Clifford Lane
- Subjects
Medical emergencies. Critical care. Intensive care. First aid ,RC86-88.9 - Abstract
OBJECTIVES:. We sought to validate prognostic scores in coronavirus disease 2019 including National Early Warning Score, Modified Early Warning Score, and age-based modifications, and define their performance characteristics. DESIGN:. We analyzed prospectively collected data from the Adaptive COVID-19 Treatment Trial. National Early Warning Score was collected daily during the trial, Modified Early Warning Score was calculated, and age applied to both scores. We assessed prognostic value for the end points of recovery, mechanical ventilation, and death for score at enrollment, average, and slope of score over the first 48 hours. SETTING:. A multisite international inpatient trial. PATIENTS:. A total of 1,062 adult nonpregnant inpatients with severe coronavirus disease 2019 pneumonia. INTERVENTIONS:. Adaptive COVID-19 Treatment Trial 1 randomized participants to receive remdesivir or placebo. The prognostic value of predictive scores was evaluated in both groups separately to assess for differential performance in the setting of remdesivir treatment. MEASUREMENTS AND MAIN RESULTS:. For mortality, baseline National Early Warning Score and Modified Early Warning Score were weakly to moderately prognostic (c-index, 0.60–0.68), and improved with addition of age (c-index, 0.66–0.74). For recovery, baseline National Early Warning Score and Modified Early Warning Score demonstrated somewhat better prognostic ability (c-index, 0.65–0.69); however, National Early Warning Score+age and Modified Early Warning Score+age further improved performance (c-index, 0.68–0.71). For deterioration, baseline National Early Warning Score and Modified Early Warning Score were weakly to moderately prognostic (c-index, 0.59–0.69) and improved with addition of age (c-index, 0.63–0.70). All prognostic performance improvements due to addition of age were significant (p < 0.05). CONCLUSIONS:. In the Adaptive COVID-19 Treatment Trial 1 cohort, National Early Warning Score and Modified Early Warning Score demonstrated moderate prognostic performance in patients with severe coronavirus disease 2019, with improvement in predictive ability for National Early Warning Score+age and Modified Early Warning Score+age. Area under receiver operating curve for National Early Warning Score and Modified Early Warning Score improved in patients receiving remdesivir versus placebo early in the pandemic for recovery and mortality. Although these scores are simple and readily obtainable in myriad settings, in our data set, they were insufficiently predictive to completely replace clinical judgment in coronavirus disease 2019 and may serve best as an adjunct to triage, disposition, and resourcing decisions.
- Published
- 2021
- Full Text
- View/download PDF
7. The Impact of 2020 Low Traffic Neighbourhoods on Fire Service Emergency Response Times, in London, UK
- Author
-
Anna Goodman, Anthony A. Laverty, Asa Thomas, and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
Between March and September 2020, 72 ‘Low Traffic Neighbourhoods’ (LTNs) were implemented in London. We examined the impact on fire brigade emergency response times in October 2020-February 2021 (‘post’), as compared to the same months in the previous two years (‘pre’). We found no evidence that response times inside the LTNs or on boundary roads were affected (e.g. pre/post change for first engine: -14 seconds inside LTNs; -11 seconds in the rest of London; p=0.4 for difference). Fire crews reported more delays due to 'traffic calming measures' in LTNs, but this was entirely offset by a decrease in delays for other reasons, particularly 'traffic'. This was true both in LTNs that predominately blocked motor traffic using physical barriers (e.g. planters) and in LTNs using camera enforcement. These findings add to evidence that LTNs do not adversely affect emergency response times.
- Published
- 2021
- Full Text
- View/download PDF
8. Short-Term Association between the Introduction of 2020 Low Traffic Neighbourhoods and Street Crime, in London, UK
- Author
-
Anna Goodman, Anthony A. Laverty, and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
Between March and September 2020, 72 ‘Low Traffic Neighbourhoods’ (LTNs) were rapidly rolled out in London under emergency legislation. We examined the association between LTN implementation and street crime in October 2020 - February 2021 (‘post’), as compared to the same months in the previous two years (‘pre’). Overall crime trends in and around LTNs were more favourable than the background trend in Outer London, and similar to or slightly more favourable than the trend in Inner London. This pattern was also seen for numbers of direct attacks against the person - and this may underestimate the benefit per pedestrian, given evidence that LTN introduction is associated with increased walking.
- Published
- 2021
- Full Text
- View/download PDF
9. The Impact of Low Traffic Neighbourhoods on Active Travel, Car Use, and Perceptions of Local Environment during the COVID-19 Pandemic
- Author
-
Rachel Aldred and Anna Goodman
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
We use longitudinal survey data to compare the impacts of ‘emergency’ low traffic neighbourhoods (LTNs), set up during Covid-19, to the impacts of longer-standing LTNs. While sample sizes are small, both types of LTNs had similar increases in active travel and similar improvements in perceptions of the local environment for cycling (but no change in perceptions of most other aspects of the local environment). Car use tended to decrease. This similarity suggests the emergency LTNs may bring benefits similar to longer-standing LTNs despite their lower budgets and shorter planning periods. We also found that the active travel impacts of the long-standing LTNs grew larger over time, suggesting the emergency LTNs may likewise see larger effects in the future.
- Published
- 2021
- Full Text
- View/download PDF
10. The Impact of Introducing a Low Traffic Neighbourhood on Street Crime, in Waltham Forest, London
- Author
-
Anna Goodman and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
Using police data, 2012-2019, we examine the impact on street crime of introducing low traffic neighbourhoods in Waltham Forest, London. Overall, the introduction of a low traffic neighbourhood was associated with a 10% decrease in total street crime (95% confidence interval 7% to 13%), and this effect increased with a longer duration since implementation (18% decrease after 3 years). An even larger reduction was observed for violence and sexual offences, the most serious subcategory of crime. The only subcategory of crime that increased significantly was bicycle theft, plausibly largely reflecting increased cycling levels. There was no indication of displacement of any crime subcategory into adjacent areas.
- Published
- 2021
- Full Text
- View/download PDF
11. The Impact of Introducing Low Traffic Neighbourhoods on Road Traffic Injuries
- Author
-
Anthony A Laverty, Rachel Aldred, and Anna Goodman
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
We examine the impact on road traffic injuries of introducing low traffic neighbourhoods in Waltham Forest, London. Using Stats19 police data 2012-2019, we find a three-fold decline in number of injuries inside low traffic neighbourhoods after implementation, relative to the rest of Waltham Forest and the rest of Outer London. We further estimate that walking, cycling, and driving all became approximately 3-4 times safer per trip. There was no evidence that injury numbers changed on boundary roads. Our findings suggest that low traffic neighbourhoods reduce injury risks across all modes inside the neighbourhood, without negative impacts at the boundary.
- Published
- 2021
- Full Text
- View/download PDF
12. Associations of active travel with adiposity among children and socioeconomic differentials: a longitudinal study
- Author
-
Anthony A Laverty, Christopher Millett, Thomas Hone, Anna Goodman, and Yvonne Kelly
- Subjects
Medicine - Abstract
Objectives Examine longitudinal associations between modes of travel to school and adiposity.Setting The UK.Participants 8432 children surveyed at ages 7, 11 and 14 years from the UK Millennium Cohort Study.Primary and secondary outcomes Objective percentage body fat and body mass index (BMI). Transport mode was categorised as private motorised transport, public transport and active transport (walking or cycling). Socioeconomic position (SEP) was measured by household income group and occupational social class. We adjusted analyses for changes in the country of UK, frequency of eating breakfast, self-reported growth spurts, hours of screen time and days per week of moderate-to-vigorous physical activity. Longitudinal (panel) regression models adjusting for individual fixed effects examined associations in changes in mode of travel to school and adiposity, controlling for both time-varying and time-invariant potential confounders. Interaction tests and stratified analyses investigated differences by markers of SEP.Results At age 14 years, 26.1% of children (2198) reported using private motorised transport, 35.3% (2979) used public transport and 38.6% (3255) used active transport to get to school. 36.6% (3083) of children changed mode two times between the three waves and 50.7% (4279) changed once. Compared with continuing to use private transport, switching to active transport was associated with a lower BMI (−0.21 kg/m2, 95% CI −0.31 to −0.10) and body fat (−0.55%, 95% CI −0.80% to −0.31%). Switching to public transport was associated with lower percentage body fat (−0.43%, 95% CI −0.75% to −0.12%), but associations with BMI did not reach statistical significance (−0.13 kg/m2, 95% CI −0.26 to 0.01). Interaction tests showed a trend for these effects to be stronger in more deprived groups, but these interactions did not reach statistical significance.Conclusion This longitudinal study during a key life course period found switching to physically active forms of travel can have beneficial adiposity impacts; these associations may be more apparent for more disadvantaged children. Increasing active travel has potential to ameliorate inequalities.
- Published
- 2021
- Full Text
- View/download PDF
13. The Impact of Low Traffic Neighbourhoods and Other Active Travel Interventions on Vehicle Ownership: Findings from the Outer London Mini-Holland Programme
- Author
-
Anna Goodman, Scott Urban, and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
We use vehicle registration data to examine whether active travel interventions in Outer London between 2015-2019 affected motor vehicle ownership, compared to other neighbourhoods. We find statistically significant reductions in car/van ownership in areas introducing ‘low traffic neighbourhoods’ (-6%, or 23 cars/vans per 1000 adults, after two years). We also find statistically significant but smaller reductions in areas introducing other infrastructure such as cycle tracks (-2%, or 7 cars/vans per 1000 adults, after 2 years). These effects increased after adjusting for the changing age profile of the intervention areas. Our findings indicate that active travel interventions can reduce motor-vehicle ownership, particularly interventions involving low traffic neighbourhoods.
- Published
- 2020
- Full Text
- View/download PDF
14. The Impact of Introducing a Low Traffic Neighbourhood on Fire Service Emergency Response Times, in Waltham Forest London
- Author
-
Anna Goodman, Anthony A Laverty, and Rachel Aldred
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
There is sometimes concern that low traffic neighbourhoods slow emergency vehicles. We test this using London Fire Brigade data (2012-2020) in Waltham Forest, where from 2015 low traffic neighbourhoods have been implemented. We find no evidence that response times were affected inside low traffic neighbourhoods, and some evidence that they improved slightly on boundary roads. However, while the proportion of delays was unchanged, the reasons given for delays initially showed some shift from ‘no specific delay cause identified’ to ‘traffic calming measures’. Our findings indicate that low traffic neighbourhoods do not adversely affect emergency response times, although while LTNs are novel this perception may exist among some crews.
- Published
- 2020
- Full Text
- View/download PDF
15. Low Traffic Neighbourhoods, Car Use, and Active Travel: Evidence from the People and Places Survey of Outer London Active Travel Interventions
- Author
-
Rachel Aldred and Anna Goodman
- Subjects
Transportation and communications ,HE1-9990 ,Urban groups. The city. Urban sociology ,HT101-395 - Abstract
This paper reports on analysis of impacts of active travel interventions in Outer London between 2016-19. We find larger effects (decreased car ownership and use, increased active travel) in intervention areas where Low Traffic Neighbourhoods (LTNs) were introduced. Decreased car ownership and use is only found in such areas. Sample size for LTN areas is small and hence uncertainty about effect magnitude is large, but effect direction is consistent. This suggests that to reduce car use as well as increase active travel, LTNs are an important part of the intervention toolbox.
- Published
- 2020
- Full Text
- View/download PDF
16. Faecal microbiota transplant to ERadicate gastrointestinal carriage of Antibiotic Resistant Organisms (FERARO): a prospective, randomised placebo-controlled feasibility trial
- Author
-
Catey Bunce, Anna Goodman, Gregory Amos, Blair Merrick, Emily Robinson, Liz Allen, Karen Bisnauthsing, Chi Chi Izundu, Jordana Bell, Manu Shankar-Hari, Debbie L Shawcross, and Simon D Goldenberg
- Subjects
Medicine - Abstract
Introduction Antimicrobial resistance is rising, largely due to the indiscriminate use of antimicrobials. The human gut is the largest reservoir of antibiotic resistant bacteria (ARB). Individuals colonised with ARB have the potential to spread these organisms both in the community and hospital settings. Infections with ARB such as extended spectrum beta-lactamase producing enterobacteriales (ESBL-E) and carbapenemase producing enterobacteriales (CPE) are more difficult to treat and are associated with an increased morbidity and mortality. Presently, there is no effective decolonisation strategy for these ARB. Faecal microbiota transplant (FMT) has emerged as a potential strategy for decolonisation of ARB from the human gut, however there is significant uncertainty about the feasibility, effectiveness and safety of using this approach.Methods and analysis Prospective, randomised, patient-blinded, placebo-controlled feasibility trial of FMT to eradicate gastrointestinal carriage of ARB. Eighty patients with a recent history of invasive infection secondary to ESBL-E or CPE and persistent gastrointestinal carriage will be randomised 1:1 to receive encapsulated FMT or placebo. The primary outcome measure is consent rate (as a proportion of patients who fulfil inclusion/exclusion criteria); this will be used to determine if a substantive trial is feasible. Participants will be followed up at 1 week, 1 month, 3 months and 6 months and monitored for adverse events as well as gastrointestinal carriage rates of ARB after intervention.Ethics and dissemination Research ethics approval was obtained by London—City and East Research Ethics Committee (ref 20/LO/0117). Trial results will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ISRCTN registration number 34 467 677 and EudraCT number 2019-001618-41.
- Published
- 2020
- Full Text
- View/download PDF
17. Health impact modelling of different travel patterns on physical activity, air pollution and road injuries for São Paulo, Brazil
- Author
-
Thiago Hérick de Sá, Marko Tainio, Anna Goodman, Phil Edwards, Andy Haines, Nelson Gouveia, Carlos Monteiro, and James Woodcock
- Subjects
Environmental sciences ,GE1-350 - Abstract
Background: São Paulo city, Brazil, faces challenges caused by rapid urbanization. We illustrate how future travel patterns could lead to different health consequences in the city. Methods: We evaluated the health impacts of different travel pattern scenarios for the São Paulo adult population by comparing the travel patterns of São Paulo in 2012 with counterfactual scenarios in which the city adopted travel patterns of i) those living in the city's expanded centre; ii) London (2012); iii) a highly motorized São Paulo (SP California); and iv) a visionary São Paulo (SP 2040), with high levels of walking and cycling and low levels of car and motorcycle use. For each scenario we estimated changes in exposure to air pollution, road injury risk, and physical activity. Health outcomes were estimated using disability adjusted life years (DALYs) and premature deaths averted. Sensitivity analyses were performed to identify the main sources of uncertainty. Results: We found considerable health gains in the SP 2040 scenario (total 63.6k DALYs avoided), with 4.7% of premature deaths from ischemic heart disease avoided from increases in physical activity alone. Conversely, we found substantial health losses in the scenario favouring private transport (SP California, total increase of 54.9k DALYs), with an increase in road traffic deaths and injuries among pedestrians and motorized vehicles. Parameters related to air pollution had the largest impact on uncertainty. Conclusions: Shifting travel patterns towards more sustainable transport can provide major health benefits in São Paulo. Reducing the uncertainties in the findings should be a priority for empirical and modelling research on the health impacts of such shifts.
- Published
- 2017
- Full Text
- View/download PDF
18. Historical Context Changes Pathways of Parental Influence on Reproduction: An Empirical Test from 20th-Century Sweden
- Author
-
Cristina Moya, Anna Goodman, Ilona Koupil, and Rebecca Sear
- Subjects
fertility ,reproductive timing ,family structure ,life history strategies ,educational attainment ,cohort effects ,Social Sciences - Abstract
Several studies have found that parental absences in childhood are associated with individuals’ reproductive strategies later in life. However, these associations vary across populations and the reasons for this heterogeneity remain debated. In this paper, we examine the diversity of parental associations in three ways. First, we test whether different kinds of parental availability in childhood and adolescence are associated with women’s and men’s ages at first birth using the intergenerational and longitudinal Uppsala Birth Cohort Study (UBCoS) dataset from Sweden. This cultural context provides a strong test of the hypothesis that parents influence life history strategies given that robust social safety nets may buffer parental absences. Second, we examine whether investments in education help explain why early parental presence is associated with delayed ages at first birth in many post-industrial societies, given that parents often support educational achievement. Third, we compare parental associations with reproductive timing across two adjacent generations in Sweden. This historical contrast allows us to control for many sources of heterogeneity while examining whether changing educational access and norms across the 20th-century change the magnitude and pathways of parental influence. We find that parental absences tend to be associated with earlier first births, and more reliably so for women. Many of these associations are partially mediated by university attendance. However, we also find important differences across cohorts. For example, the associations with paternal death become similar for sons and daughters in the more recent cohort. One possible explanation for this finding is that fathers start influencing sons and daughters more similarly. Our results illustrate that historical changes within a population can quickly shift how family affects life history.
- Published
- 2021
- Full Text
- View/download PDF
19. Weather and children’s physical activity; how and why do relationships vary between countries?
- Author
-
Flo Harrison, Anna Goodman, Esther M. F. van Sluijs, Lars Bo Andersen, Greet Cardon, Rachel Davey, Kathleen F Janz, Susi Kriemler, Lynn Molloy, Angie S Page, Russ Pate, Jardena J Puder, Luis B Sardinha, Anna Timperio, Niels Wedderkopp, Andy P. Jones, and on behalf the ICAD collaborators
- Subjects
ICAD ,Child ,Adolescent ,Physical activity ,Season ,Weather ,Nutritional diseases. Deficiency diseases ,RC620-627 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Globally most children do not engage in enough physical activity. Day length and weather conditions have been identified as determinants of physical activity, although how they may be overcome as barriers is not clear. We aim to examine if and how relationships between children’s physical activity and weather and day length vary between countries and identify settings in which children were better able to maintain activity levels given the weather conditions they experienced. Methods In this repeated measures study, we used data from 23,451 participants in the International Children’s Accelerometry Database (ICAD). Daily accelerometer-measured physical activity (counts per minute; cpm) was matched to local weather conditions and the relationships assessed using multilevel regression models. Multilevel models accounted for clustering of days within occasions within children within study-cities, and allowed us to explore if and how the relationships between weather variables and physical activity differ by setting. Results Increased precipitation and wind speed were associated with decreased cpm while better visibility and more hours of daylight were associated with increased cpm. Models indicated that increases in these variables resulted in average changes in mean cpm of 7.6/h of day length, −13.2/cm precipitation, 10.3/10 km visibility and −10.3/10kph wind speed (all p
- Published
- 2017
- Full Text
- View/download PDF
20. Development of the Impacts of Cycling Tool (ICT): A modelling study and web tool for evaluating health and environmental impacts of cycling uptake.
- Author
-
James Woodcock, Ali Abbas, Alvaro Ullrich, Marko Tainio, Robin Lovelace, Thiago H Sá, Kate Westgate, and Anna Goodman
- Subjects
Medicine - Abstract
BackgroundA modal shift to cycling has the potential to reduce greenhouse gas emissions and provide health co-benefits. Methods, models, and tools are needed to estimate the potential for cycling uptake and communicate to policy makers the range of impacts this would have.Methods and findingsThe Impacts of Cycling Tool (ICT) is an open source model with a web interface for visualising travel patterns and comparing the impacts of different scenarios of cycling uptake. It is currently applied to England. The ICT allows users to visualise individual and trip-level data from the English National Travel Survey (NTS), 2004-2014 sample, 132,000 adults. It models scenarios in which there is an increase in the proportion of the population who cycle regularly, using a distance-based propensity approach to model which trips would be cycled. From this, the model estimates likely impact on travel patterns, health, and greenhouse gas emissions. Estimates of nonoccupational physical activity are generated by fusing the NTS with the English Active People Survey (APS, 2013-2014, 559,515 adults) to create a synthetic population. Under 'equity' scenarios, we investigate what would happen if cycling levels increased equally among all age and gender categories, as opposed to in proportion to the profile of current cyclists. Under electric assist bike (pedelecs or 'e-bike') scenarios, the probability of cycling longer trips increases, based on the e-bike data from the Netherlands, 2013-2014 Dutch Travel Survey (50,868 adults).Outcomes are presented across domains including transport (trip duration and trips by mode), health (physical activity levels, years of life lost), and car transport-related CO2 emissions. Results can be visualised for the whole population and various subpopulations (region, age, gender, and ethnicity). The tool is available at www.pct.bike/ict. If the proportion of the English population who cycle regularly increased from 4.8% to 25%, then there would be notable reductions in car miles and passenger related CO2 emissions (2.2%) and health benefits (2.1% reduction in years of life lost due to premature mortality). If the new cyclists had access to e-bikes, then mortality reductions would be similar, while the reduction in car miles and CO2 emissions would be larger (2.7%). If take-up of cycling occurred equally by gender and age (under 80 years), then health benefits would be marginally greater (2.2%) but reduction in CO2 slightly smaller (1.8%). The study is limited by the quality and comparability of the input data (including reliance on self-report behaviours). As with all modelling studies, many assumptions are required and potentially important pathways excluded (e.g. injury, air pollution, and noise pollution).ConclusionThis study demonstrates a generalisable approach for using travel survey data to model scenarios of cycling uptake that can be applied to a wide range of settings. The use of individual-level data allows investigation of a wide range of outcomes, and variation across subgroups. Future work should investigate the sensitivity of results to assumptions and omissions, and if this varies across setting.
- Published
- 2018
- Full Text
- View/download PDF
21. The current and potential health benefits of the National Health Service Health Check cardiovascular disease prevention programme in England: A microsimulation study.
- Author
-
Oliver T Mytton, Christopher Jackson, Arno Steinacher, Anna Goodman, Claudia Langenberg, Simon Griffin, Nick Wareham, and James Woodcock
- Subjects
Medicine - Abstract
BackgroundThe National Health Service (NHS) Health Check programme was introduced in 2009 in England to systematically assess all adults in midlife for cardiovascular disease risk factors. However, its current benefit and impact on health inequalities are unknown. It is also unclear whether feasible changes in how it is delivered could result in increased benefits. It is one of the first such programmes in the world. We sought to estimate the health benefits and effect on inequalities of the current NHS Health Check programme and the impact of making feasible changes to its implementation.Methods and findingsWe developed a microsimulation model to estimate the health benefits (incident ischaemic heart disease, stroke, dementia, and lung cancer) of the NHS Health Check programme in England. We simulated a population of adults in England aged 40-45 years and followed until age 100 years, using data from the Health Survey of England (2009-2012) and the English Longitudinal Study of Aging (1998-2012), to simulate changes in risk factors for simulated individuals over time. We used recent programme data to describe uptake of NHS Health Checks and of 4 associated interventions (statin medication, antihypertensive medication, smoking cessation, and weight management). Estimates of treatment efficacy and adherence were based on trial data. We estimated the benefits of the current NHS Health Check programme compared to a healthcare system without systematic health checks. This counterfactual scenario models the detection and treatment of risk factors that occur within 'routine' primary care. We also explored the impact of making feasible changes to implementation of the programme concerning eligibility, uptake of NHS Health Checks, and uptake of treatments offered through the programme. We estimate that the NHS Health Check programme prevents 390 (95% credible interval 290 to 500) premature deaths before 80 years of age and results in an additional 1,370 (95% credible interval 1,100 to 1,690) people being free of disease (ischaemic heart disease, stroke, dementia, and lung cancer) at age 80 years per million people aged 40-45 years at baseline. Over the life of the cohort (i.e., followed from 40-45 years to 100 years), the changes result in an additional 10,000 (95% credible interval 8,200 to 13,000) quality-adjusted life years (QALYs) and an additional 9,000 (6,900 to 11,300) years of life. This equates to approximately 300 fewer premature deaths and 1,000 more people living free of these diseases each year in England. We estimate that the current programme is increasing QALYs by 3.8 days (95% credible interval 3.0-4.7) per head of population and increasing survival by 3.3 days (2.5-4.1) per head of population over the 60 years of follow-up. The current programme has a greater absolute impact on health for those living in the most deprived areas compared to those living in the least deprived areas (4.4 [2.7-6.5] days of additional quality-adjusted life per head of population versus 2.8 [1.7-4.0] days; 5.1 [3.4-7.1] additional days lived per head of population versus 3.3 [2.1-4.5] days). Making feasible changes to the delivery of the existing programme could result in a sizable increase in the benefit. For example, a strategy that combines extending eligibility to those with preexisting hypertension, extending the upper age of eligibility to 79 years, increasing uptake of health checks by 30%, and increasing treatment rates 2.5-fold amongst eligible patients (i.e., 'maximum potential' scenario) results in at least a 3-fold increase in benefits compared to the current programme (1,360 premature deaths versus 390; 5,100 people free of 1 of the 4 diseases versus 1,370; 37,000 additional QALYs versus 10,000; 33,000 additional years of life versus 9,000). Ensuring those who are assessed and eligible for statins receive statins is a particularly important strategy to increase benefits. Estimates of overall benefit are based on current incidence and management, and future declines in disease incidence or improvements in treatment could alter the actual benefits observed in the long run. We have focused on the cardiovascular element of the NHS Health Check programme. Some important noncardiovascular health outcomes (e.g., chronic obstructive pulmonary disease [COPD] prevention from smoking cessation and cancer prevention from weight loss) and other parts of the programme (e.g., brief interventions to reduce harmful alcohol consumption) have not been modelled.ConclusionsOur model indicates that the current NHS Health Check programme is contributing to improvements in health and reducing health inequalities. Feasible changes in the organisation of the programme could result in more than a 3-fold increase in health benefits.
- Published
- 2018
- Full Text
- View/download PDF
22. Estimating city-level travel patterns using street imagery: A case study of using Google Street View in Britain.
- Author
-
Rahul Goel, Leandro M T Garcia, Anna Goodman, Rob Johnson, Rachel Aldred, Manoradhan Murugesan, Soren Brage, Kavi Bhalla, and James Woodcock
- Subjects
Medicine ,Science - Abstract
BackgroundStreet imagery is a promising and growing big data source providing current and historical images in more than 100 countries. Studies have reported using this data to audit road infrastructure and other built environment features. Here we explore a novel application, using Google Street View (GSV) to predict travel patterns at the city level.MethodsWe sampled 34 cities in Great Britain. In each city, we accessed 2000 GSV images from 1000 random locations. We selected archived images from time periods overlapping with the 2011 Census and the 2011-2013 Active People Survey (APS). We manually annotated the images into seven categories of road users. We developed regression models with the counts of images of road users as predictors. The outcomes included Census-reported commute shares of four modes (combined walking plus public transport, cycling, motorcycle, and car), as well as APS-reported past-month participation in walking and cycling.ResultsWe found high correlations between GSV counts of cyclists ('GSV-cyclists') and cycle commute mode share (r = 0.92)/past-month cycling (r = 0.90). Likewise, GSV-pedestrians was moderately correlated with past-month walking for transport (r = 0.46), GSV-motorcycles was moderately correlated with commute share of motorcycles (r = 0.44), and GSV-buses was highly correlated with commute share of walking plus public transport (r = 0.81). GSV-car was not correlated with car commute mode share (r = -0.12). However, in multivariable regression models, all outcomes were predicted well, except past-month walking. The prediction performance was measured using cross-validation analyses. GSV-buses and GSV-cyclists are the strongest predictors for most outcomes.ConclusionsGSV images are a promising new big data source to predict urban mobility patterns. Predictive power was the greatest for those modes that varied the most (cycle and bus). With its ability to identify mode of travel and capture street activity often excluded in routinely carried out surveys, GSV has the potential to be complementary to new and traditional data. With half the world's population covered by street imagery, and with up to 10 years historical data available in GSV, further testing across multiple settings is warranted both for cross-sectional and longitudinal assessments.
- Published
- 2018
- Full Text
- View/download PDF
23. Social class, social mobility and alcohol-related disorders in Swedish men and women: A study of four generations.
- Author
-
Anna Sidorchuk, Anna Goodman, and Ilona Koupil
- Subjects
Medicine ,Science - Abstract
To investigate whether and how social class and social mobility in grandparents and parents predict alcohol-related disorders (ARDs) in males and females aged 12+ years, and whether intergenerational social prediction of ARDs varies across time periods.The study sample included four successive generations (G) of Swedish families from the Uppsala Birth Cohort Multigenerational Study: G0 born 1851-1912; G1 born 1915-1929; G2 born 1940-1964 and G3 born 1965-1989. Two study populations were created, each consisting of grandparents, parents and offspring: population I 'G0-G1-G2' (offspring n = 18 430) and population II 'G1-G2-G3' (offspring n = 26 469). Registers and archives provided data on ancestors' socio-demographic factors and ARD history, together with offspring ARD development between 1964-2008. Cox regression models examined the hazard of offspring ARD development according to grandparental social class and grandparental-to-parental social trajectories, controlling for offspring birth year, grandmother's and mother's marital status and parental ARDs.Disadvantaged grandparental social class predicted increased ARD risk in offspring in population I, although the effect attenuated and became non-significant in males after adjusting for parental characteristics (adjusted hazard ratio (HR) = 1.80 (95%CI; 1.07, 3.03) in females, HR = 1.32 (95%CI; 0.93, 1.89) in males). In population II, no increase in ARD risk by grandparental social was evident. In both populations, males were at the highest ARD risk if both parents and grandparents belonged to disadvantaged social class (population I: HR = 1.82 (95%CI; 1.22-2.72); population II: HR = 1.68 (95%CI; 1.02-2.76)).Intergenerational social patterning of ARDs appears to be time-contextual and gender-specific. The role of grandparental social class in developing ARDs in grandchildren seems to decline over time, while persistent grandparental-to-parental social disadvantage remains associated with higher ARD risk in males. When targeting higher risk groups, continuity of familial social disadvantage, particularly among males, should be considered.
- Published
- 2018
- Full Text
- View/download PDF
24. The Propensity to Cycle Tool: An open source online system for sustainable transport planning
- Author
-
Robin Lovelace, Anna Goodman, Rachel Aldred, Nikolai Berkoff, Ali Abbas, and James Woodcock
- Subjects
Cycling ,Planning ,Modelling ,Participatory ,Transportation engineering ,TA1001-1280 ,Transportation and communications ,HE1-9990 - Abstract
Getting people cycling is an increasingly common objective in transport planning institutions worldwide. A growing evidence base indicates that high quality infrastructure can boost local cycling rates. Yet for infrastructure and other cycling measures to be effective, it is important to intervene in the right places, such as along ‘desire lines’ of high latent demand. This creates the need for tools and methods to help answer the question ‘where to build?’. Following a brief review of the policy and research context related to this question, this paper describes the design, features and potential applications of such a tool. The Propensity to Cycle Tool (PCT) is an online, interactive planning support system that was initially developed to explore and map cycling potential across England (see www.pct.bike). Based on origin-destination data it models cycling levels at area, desire line, route and route network levels, for current levels of cycling, and for scenario-based ‘cycling futures.’ Four scenarios are presented, including ‘Go Dutch’ and ‘Ebikes,’ which explore what would happen if English people had the same propensity to cycle as Dutch people and the potential impact of electric cycles on cycling uptake. The cost effectiveness of investment depends not only on the number of additional trips cycled, but on wider impacts such as health and carbon benefits. The PCT reports these at area, desire line, and route level for each scenario. The PCT is open source, facilitating the creation of scenarios and deployment in new contexts. We conclude that the PCT illustrates the potential of online tools to inform transport decisions and raises the wider issue of how models should be used in transport planning.
- Published
- 2017
- Full Text
- View/download PDF
25. Using inferred probabilities to measure the accuracy of imprecise forecasts
- Author
-
Paul Lehner, Avra Michelson, Leonard Adelman, and Anna Goodman
- Subjects
inferred probability ,imputed probability ,judgment-based forecasting ,forecast accuracy ,imprecise forecasts ,political forecasting ,verbal probability ,probability calibration ,Social Sciences ,Psychology ,BF1-990 - Abstract
Research on forecasting is effectively limited to forecasts that are expressed with clarity; which is to say that the forecasted event must be sufficiently well-defined so that it can be clearly resolved whether or not the event occurred and forecasts certainties are expressed as quantitative probabilities. When forecasts are expressed with clarity, then quantitative measures (scoring rules, calibration, discrimination, etc.) can be used to measure forecast accuracy, which in turn can be used to measure the comparative accuracy of different forecasting methods. Unfortunately most real world forecasts are not expressed clearly. This lack of clarity extends to both the description of the forecast event and to the use of vague language to express forecast certainty. It is thus difficult to assess the accuracy of most real world forecasts, and consequently the accuracy the methods used to generate real world forecasts. This paper addresses this deficiency by presenting an approach to measuring the accuracy of imprecise real world forecasts using the same quantitative metrics routinely used to measure the accuracy of well-defined forecasts. To demonstrate applicability, the inferred probability method is applied to measure the accuracy of forecasts in fourteen documents examining complex political domains.
- Published
- 2012
- Full Text
- View/download PDF
26. On the buses: a mixed-method evaluation of the impact of free bus travel for young people on the public health
- Author
-
Judith Green, Rebecca Steinbach, Alasdair Jones, Phil Edwards, Charlotte Kelly, John Nellthorp, Anna Goodman, Helen Roberts, Mark Petticrew, and Paul Wilkinson
- Subjects
bus travel ,public health ,london ,young people ,older citizens ,mixed method ,Public aspects of medicine ,RA1-1270 - Abstract
Background: In September 2005 London introduced a policy granting young people aged 60 years. An increase in assaults largely preceded the scheme. Qualitative data suggested that the scheme increased opportunities for independent travel, social inclusion, and a sense of belonging and that it ‘normalised’ bus travel. The monetised benefits of the scheme substantially outweighed the costs, providing what the Department for Transport (DfT) considers ‘high’ value for money. Conclusion: The free bus travel scheme for young people appears to have encouraged their greater use of bus transport for short trips without significant impact on their overall active travel. There was qualitative evidence for benefits on social determinants of health, such as normalisation of bus travel, greater social inclusion and opportunities for independent travel. In the context of a good bus service, universal free bus travel for young people appears to be a cost-effective contributor to social inclusion and, potentially, to increasing sustainable transport in the long term. Further research is needed on the effects of both active and other travel modes on the determinants of health; the factors that influence maintenance of travel mode change; travel as ‘social practice’; the impact of driving license changes on injury rates for young adults and the value of a statistical life for young people. Funding: The National Institute for Health Research Public Health Research programme.
- Published
- 2014
- Full Text
- View/download PDF
27. Family history of education predicts eating disorders across multiple generations among 2 million Swedish males and females.
- Author
-
Anna Goodman, Amy Heshmati, and Ilona Koupil
- Subjects
Medicine ,Science - Abstract
To investigate which facets of parent and grandparent socio-economic position (SEP) are associated with eating disorders (ED), and how this varies by ED subtype and over time.Total-population cohort study of 1,040,165 females and 1,098,188 males born 1973-1998 in Sweden, and followed for inpatient or outpatient ED diagnoses until 2010. Proportional hazards models estimated associations with parental education, income and social class, and with grandparental education and income.15,747 females and 1051 males in our sample received an ED diagnosis, with rates increasing in both sexes over time. ED incidence in females was independently predicted by greater educational level among the father, mother and maternal grandparents, but parent social class and parental income showed little or no independent effect. The associations with education were equally strong for anorexia nervosa, bulimia nervosa and ED not-otherwise-specified, and had increased over time. Among males, an apparently similar pattern was seen with respect to anorexia nervosa, but non-anorexia ED showed no association with parental education and an inverse association with parental income.Family history of education predicts ED in gender- and disorder-specific ways, and in females the effect is observed across multiple generations. Particularly given that these effects may have grown stronger in more recent cohorts, these findings highlight the need for further research to clarify the underlying mechanisms and identify promising targets for prevention. Speculatively, one such mechanism may involve greater internal and external demands for academic success in highly educated families.
- Published
- 2014
- Full Text
- View/download PDF
28. Walking, cycling and driving to work in the English and Welsh 2011 census: trends, socio-economic patterning and relevance to travel behaviour in general.
- Author
-
Anna Goodman
- Subjects
Medicine ,Science - Abstract
Increasing walking and cycling, and reducing motorised transport, are health and environmental priorities. This paper examines levels and trends in the use of different commute modes in England and Wales, both overall and with respect to small-area deprivation. It also investigates whether commute modal share can serve as a proxy for travel behaviour more generally.23.7 million adult commuters reported their usual main mode of travelling to work in the 2011 census in England and Wales; similar data were available for 1971-2001. Indices of Multiple Deprivation were used to characterise socio-economic patterning. The National Travel Survey (2002-2010) was used to examine correlations between commute modal share and modal share of total travel time. These correlations were calculated across 150 non-overlapping populations defined by region, year band and income.Among commuters in 2011, 67.1% used private motorised transport as their usual main commute mode (-1.8 percentage-point change since 2001); 17.8% used public transport (+1.8% change); 10.9% walked (-0.1% change); and 3.1% cycled (+0.1% change). Walking and, to a marginal extent, cycling were more common among those from deprived areas, but these gradients had flattened over the previous decade to the point of having essentially disappeared for cycling. In the National Travel Survey, commute modal share and total modal share were reasonably highly correlated for private motorised transport (r = 0.94), public transport (r = 0.96), walking (r = 0.88 excluding London) and cycling (r = 0.77).England and Wales remain car-dependent, but the trends are slightly more encouraging. Unlike many health behaviours, it is more common for socio-economically disadvantaged groups to commute using physically active modes. This association is, however, weakening and may soon reverse for cycling. At a population level, commute modal share provides a reasonable proxy for broader travel patterns, enhancing the value of the census in characterising background trends and evaluating interventions.
- Published
- 2013
- Full Text
- View/download PDF
29. Sibling configuration predicts individual and descendant socioeconomic success in a modern post-industrial society.
- Author
-
David W Lawson, Arijeta Makoli, and Anna Goodman
- Subjects
Medicine ,Science - Abstract
Growing up with many siblings, at least in the context of modern post-industrial low fertility, low mortality societies, is predictive of relatively poor performance on school tests in childhood, lower levels of educational attainment, and lower income throughout adulthood. Recent studies further indicate these relationships hold across generations, so that the descendants of those who grow up with many siblings are also at an apparent socioeconomic disadvantage. In this paper we add to this literature by considering whether such relationships interact with the sex and relative age of siblings. To do this we utilise a unique Swedish multigenerational birth cohort study that provides sibling configuration data on over 10,000 individuals born in 1915-1929, plus all their direct genetic descendants to the present day. Adjusting for parental and birth characteristics, we find that the 'socioeconomic cost' of growing up in a large family is independent of both the sex of siblings and the sex of the individual. However, growing up with several older as opposed to several younger siblings is predictive of relatively poor performance on school tests and a lower likelihood of progression to tertiary education. This later-born disadvantage also holds across generations, with the children of those with many older siblings achieving lower levels of educational attainment. Despite these differences, we find that while individual and descendant income is negatively related to the number of siblings, it is not influenced by the relative age of siblings. Thus, our findings imply that the educational disadvantage of later-born children, demonstrated here and in numerous other studies, does not necessarily translate into reduced earnings in adulthood. We discuss potential explanations for this pattern of results, and consider some important directions for future research into sibling configuration and wellbeing in modern societies.
- Published
- 2013
- Full Text
- View/download PDF
30. Defining Environmental Health Literacy
- Author
-
Hoover, Anna Goodman, Finn, Symma, editor, and O'Fallon, Liam R., editor
- Published
- 2019
- Full Text
- View/download PDF
31. Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study
- Author
-
Douglas L Fink, Helen Callaby, Akish Luintel, William Beynon, Helena Bond, Eleanor Y Lim, Effrossyni Gkrania-Klotsas, Jospeh Heskin, Margherita Bracchi, Balram Rathish, Iain Milligan, Geraldine O'Hara, Stephanie Rimmer, Joanna R Peters, Lara Payne, Nisha Mody, Bethany Hodgson, Penny Lewthwaite, Rebecca Lester, Stephen D Woolley, Ann Sturdy, Ashley Whittington, Leann Johnson, Nathan Jacobs, John Quartey, Brendan AI Payne, Stewart Crowe, Ivo AM Elliott, Thomas Harrison, Joby Cole, Katie Beard, Tomas-Paul Cusack, Imogen Jones, Rishi Banerjee, Tommy Rampling, Jake Dunning, Iain D Milligan, Alison J Rodger, Sanjay R Bhagani, Lucy E Lamb, Rachel C Moores, Simon F K Lee, Colin S Brown, Susan Hopkins, Stephen Mepham, Simon Warren, Aoife Molloy, Ian Cropley, Alex Kew, Natasha Karunaharan, Antonia Scobie, Jennifer Hart, Dianne Irish, Tanzina Haque, Hamid Jalal, Robin Smith, Damien Mack, Tristan Barber, Fiona Burns, Robert Miller, Eleanor Hamlyn, Pedro Simoes, Breda Athan, Jennifer Abrahamsen, Jessica Joyce, Caroline Taylor, Sally Reddecliffe, Chloe Miller, Brooke Reeve, Hugh Kingston, Tim Crocker-Buque, Nicolas Massie, Ankush Dhariwal, Angelina Jayakumar, Robert Hammond, Alexandra Bramley, Tanmay Kanitkar, Laura Maynard-Smith, Eliza Gil, Cavan O'Connor, Derek Cocker, Wendy Spicer, Marisa Lanzman, Meera Thacker, Zoe O Anorson, Dharmesh Patel, Alan Williams, Catherine F Houlihan, Dominic Wakerley, Claire N Gordon, Daniel J Bailey, Jenna Furneaux, Abbie M Bown, Elizabeth J Truelove, Marian J Killip, David Jackson, Tracy L B Beetar-King, Ulrike M V Arnold, Rhea M Strachan, Jones Matthew, Hannah J Matthew, Jane C Osborne, Richard Vipond, Barry Gibney, Jodie Owen, Will Beynon, Michael Hunter, Louise McCorry, Carol Emerson, Say Quah, Suzanne Todd, Emma McCarty, Eoin Walker, Susan Feeney, Tanya Curran, Kathy Li, JD Mullan, Kate Jackson, Peter Nelson, Kevin Lewis, Mark McNicol, Marcus Pratt, Anna Smith, Erin Vos, Fahad Alsalemee, Daniel O Leary, John Canny, Katherine McGinnity, Carly Culbert, Conor McDowell, Cathy McQuillan, Eunjin Jeong, Lynsey Glass, Jessica Dyche, Paula McClean, Rebecca Stewart, Harold Ursolino, Melissa Perry, Hannah McCormick, Joseph Heskin, Nicklas Brown, Thomas Juniper, Borja Mora-Peris, Alessia Dalla-Pria, Nicola Mackie, Lucy Garvey, Alan Winston, Graham Cooke, Mark Nelson, Emer Kilbride, Ala Elbishi, William Kerrigan, Joshua Silva, Jesal Gohil, Sasha Payagala, Yasmin Walters, Joanna Smith, Jonathan Goodfellow, Kitty Lyons, Hsiu Tung, Kinjal Patel, Merle Henderson, Michael Butler, Edu Peres, Taiana Silva Carvalho, Antoine Joly, Molly Dickinson, Luke S P Moore, Nabeela Mughal, Stephen Hughes, Shrada Chitlangia, Priyanka Viramgana, Ruth Byrne, Paul Randell, Luigi Strangis, Nicola Poveda, Deborah Bovey, Poppy Richardson, Vivian Heaslip, Christopher Higgs, Marta Boffito, Nicolo Girometti, Gary Whitlock, Victoria Tittle, Rachel Jones, Michael Rayment, Christopher Scott, David Asboe, Marcus Pond, David Muir, Movin Abeywickrema, Sarah-Lou Bailey, Sara E Boyd, Dayana Da Silva Fontoura, Anna Daunt, Claire Y Mason, Jamie Murphy, Vasanth V Naidu, Aatish Patel, Caitlin Pley, Ethan Redmore, Katherine Sharrocks, Luke B Snell, Rohan Sundramoorthi, Jerry C H Tam, Aisling Brown, Sam Douthwaite, Anna Goodman, Gaia Nebbia, William Newsholme, Nicholas Price, Emily Shaw, Alex Salam, Claire van Nispen tot Pannerden, Helen Winslow, Julia Bilinska, Sarah Keegan, Harry Coleman, Jessica Doctor, Nasreen Moini, Daniella Chilton, Golaleh Haidari, Rebecca Simons, Rajababu Kulasegaram, Nick Larbalestier, Achyuta Nori, Jack R Potter, Cecilia Tuudah, Paul Wade, Alexandra Travers, Sarah Dunford, Joshua Greenwood, Georgina Oledimmah, Lesley Gyampo, Pedro SA Pinto, AbdulKadir Muse, Zoe Parker, Charlotte Alexander, Alexander Khan, Medinat Ajayi, Abigail Baltazar, Davis Sharella, Nasra Hersi, Thuy Nguyen, Rugiatu Timbo, Ismail Jalloh, Susan Bryan, Patricia Clarke, Marcia Kerr, Fidelis Amedu, Maria BohoBonaba, Sarah Haque, Michelle Howson, Norbai Tambilawan, Soledad Yupanqui Estay, Hawanatu Bangura, Tseday Gideon, Damilola Jerome-oboh, Linda Tetteh, Chioma Nwagu, Viwoalo Agbaglah, Nona Narag, Mahima Zaveri, Maedhbh Ni Luanaigh, Peggy Keane, Aula Abbara, Olamide Dosekun, Mhairi Bolland, Adam Stafford, Dina Saleh, Rhianna Sheridan, Ella Davies, Kristi Sun, Mark Gilchrist, Priti Kukadia, Muhammed Embrahimsa, Christopher Chiu, Lauren Taylor, Charlotte Short, Jasmini Alagratnam, Iresh Jayaweera, Kavitha Gundugola, Lara V S Payne, Killian Quinn, Caoimhe Nic Fhogartaigh, Nivenjit Kaur, Salmaan Bholah, Kajann Kantha, Jonathan Youngs, Temi Lampejo, Nicholas Pitto, David S Lawrence, Holly Middleditch, Lourdes Dominguez-Dominguez, Ayoma Ratnappuli, Sara Al-Hashimi, Amelia Oliveira, Zoe Ottaway, Larissa Mulka, Anne M Neary, Michael R Downey, Danielle C Lucy, Craig I McCallum, Michael Beadsworth, Libuse Ratcliffe, Tom E Fletcher, Gerry Davies, Nicholas Wong, Stephen Aston, Thomas E Wingfield, Thomas Blanchard, Paul Hine, Susie Gould, Christopher Smith, Michael Abouyannis, Abolaji Atomode, James Cruise, Merna Samual, Nicola Scott, Vino Srirathan, Joseph Lewis, Lauren Richards, Mary-Ann Cummings, Emily Gillan, Rebecca Peers, Amy Tickle, Grace Keating, Tendi Chinyanda, Mav Sanchez, Daniel Harrison, null Hoyle, Ben Metcalfe, Jennifer Taylor, Nicky Johnson, Neil Kelle, Kirsty McDowell, Ian Richardson, Monette Saguidan, Nicky Farmer, Angella Gillespie, Shay Willoughby, Samantha Parker, Shamseena Avulan, Shazia Arif, Suzanne Marshall, David Carlisle, Mohsen Rezaei, Angela Booth, Joanne Watts, Lauren Tremarco, Priyanga Jeyanayagam, Odinaka Ubochi, Daniel Vagianos, Mark Richardson, Anthony Jarvis, Kyra Gow, Jade Walmsley, Adam O'keefe, Anna Smielewska, Mark Hopkins, Fatima Balane, Sarah Bradley, Tumena Corrah, Venus Daquiz, Christopher Dugan, Joshua Elliot, Fiona Foley, Dawn Friday, May Gamit, David Garner, Karishma Gokani, Laurence John, Deepa Joseph, Nuzhath Khan, Cherifer Mamuyac, Alastair McGregor, John McSorley, Victoria Parris, Luciana Rubinstein, Julian Rycroft, Kelcy Salinas, Jason Salinas, Jency Sebatian, Melanie Smith, Marina Tejero Garcia, Uchenna Ume, Margarete Vicentine, Gabriel Wallis, Alec Bonington, Alison Uriel, Andrew Ustianowski, Balazs Dancso, Celia Hogan, Clare van Halsema, F Javier Vilar, Karen Devine, Katherine Ajdukiewicz, Rajesh Rajendran, Samit Ghosh, Michael Riste, Nicholas Machin, Chitra Babu, Shazaad Ahmad, Dorcas Obeng, Farnaz Dave, Gavin Conolley, Joseph Thompson, Maya Tickell-Painter, Prasun Chakravorty, Rachel Pringle, Mohammad R Zafar, Sarah Lawrence, Amada Sanchez-Gonzalez, Cristina Fernandez, Lynsey Goodwin, David Carey, Molly Howarth-Maddison, Samuel Moody, Rebecca Upton, Christina Apthorp, Charlotte Murray, Kirstie Salthouse, Sabah Nadeem, Grant Ridley, Francesca White, Andrew Brown, Michael Lawless, Mohamed Mohamed, Robert Mulligan, Amy Belfield, Jacob Brolly, Maria Calderon, James Cheveau, Milo Cullinan, Sophie Garrad, Will Griffiths, Aidan Ireland, Peter Ireland, Charlotte Milne, Paul Nwajiugo, Bijan Ghavami-Kia, Chris Duncan, Adam Evans, Ewan Hunter, Ashley Price, Matthias Schmid, Uli Schwab, Yusri Taha, Brendan Payne, Ivo A M Elliott, Charles J Woodrow, Drosos E Karageorgopoulos, Peter J Davis, Emily Lord, Oliver J Bannister, Andrew B Dagens, Anne Tunbridge, Saher Choudry, Adam Telfer, Ihsan Jhibril, Syed N Atta, Ben Stone, Cariad Evans, Mike Ankcorn, Suha Akili, Mehmet Yavuz, Vicky Goodall, Sam Farrow, Georgina Mountford, Kate Beard, Julian Sutton, Tristan Clark, Annette Mason, Mike Vickers, Derek Macallan, Tihana Bicanic, Angela Houston, Cassie Pope, NgeeKeong Tan, Christopher Ward, Jonathan Cohen, Marieke Emonts-le Clercq, David Porter, Andrew Riordan, Ruchi Sinha, Elizabeth Whittaker, and Monkeypox, Specialist and High Consequence Infectious Diseases Centres Network for
- Subjects
Infectious Diseases - Abstract
Background:The scale of the 2022 global mpox (formerly known as monkeypox) outbreak has been unprecedented. In less than 6 months, non-endemic countries have reported more than 67 000 cases of a disease that had previously been rare outside of Africa. Mortality has been reported as rare but hospital admission has been relatively common. We aimed to describe the clinical and laboratory characteristics and outcomes of individuals admitted to hospital with mpox and associated complications, including tecovirimat recipients. Methods:In this cohort study, we undertook retrospective review of electronic clinical records and pathology data for all individuals admitted between May 6, and Aug 3, 2022, to 16 hospitals from the Specialist and High Consequence Infectious Diseases Network for Monkeypox. The hospitals were located in ten cities in England and Northern Ireland. Inclusion criteria were clinical signs consistent with mpox and MPXV DNA detected from at least one clinical sample by PCR testing. Patients admitted solely for isolation purposes were excluded from the study. Key outcomes included admission indication, complications (including pain, secondary infection, and mortality) and use of antibiotic and anti-viral treatments. Routine biochemistry, haematology, microbiology, and virology data were also collected. Outcomes were assessed in all patients with available data. Findings:156 individuals were admitted to hospital with complicated mpox during the study period. 153 (98%) were male and three (2%) were female, with a median age of 35 years (IQR 30–44). Gender data were collected from electronic patient records, which encompassed full formal review of clincian notes. The prespecified options for data collection for gender were male, female, trans, non-binary, or unknown. 105 (71%) of 148 participants with available ethnicity data were of White ethnicity and 47 (30%) of 155 were living with HIV with a median CD4 count of 510 cells per mm3(IQR 349–828). Rectal or perianal pain (including proctitis) was the most common indication for hospital admission (44 [28%] of 156). Severe pain was reported in 89 (57%) of 156, and secondary bacterial infection in 82 (58%) of 142 individuals with available data. Median admission duration was 5 days (IQR 2–9). Ten individuals required surgery and two cases of encephalitis were reported. 38 (24%) of the 156 individuals received tecovirimat with early cessation in four cases (two owing to hepatic transaminitis, one to rapid treatment response, and one to patient choice). No deaths occurred during the study period. Interpretation:Although life-threatening mpox appears rare in hospitalised populations during the current outbreak, severe mpox and associated complications can occur in immunocompetent individuals. Analgesia and management of superimposed bacterial infection are priorities for patients admitted to hospital.
- Published
- 2023
32. Invited Perspective: Making the Implicit Explicit—Connecting Environmental Health Literacy and Exposure Report-Back
- Author
-
Hoover, Anna Goodman, primary
- Published
- 2023
- Full Text
- View/download PDF
33. Classifying Community Organizational Health Communication Networks: Local Health Department Recognition of Public Information-Sharing Partners Across Sectors
- Author
-
Hoover, Anna Goodman and Zephyr, Pierre Dominique
- Published
- 2020
- Full Text
- View/download PDF
34. Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC) : an open-label, platform-adaptive randomised controlled trial
- Author
-
Christopher C Butler, F D Richard Hobbs, Oghenekome A Gbinigie, Najib M Rahman, Gail Hayward, Duncan B Richards, Jienchi Dorward, David M Lowe, Joseph F Standing, Judith Breuer, Saye Khoo, Stavros Petrou, Kerenza Hood, Jonathan S Nguyen-Van-Tam, Mahendra G Patel, Benjamin R Saville, Joe Marion, Emma Ogburn, Julie Allen, Heather Rutter, Nick Francis, Nicholas P B Thomas, Philip Evans, Melissa Dobson, Tracie-Ann Madden, Jane Holmes, Victoria Harris, May Ee Png, Mark Lown, Oliver van Hecke, Michelle A Detry, Christina T Saunders, Mark Fitzgerald, Nicholas S Berry, Lazaro Mwandigha, Ushma Galal, Sam Mort, Bhautesh D Jani, Nigel D Hart, Haroon Ahmed, Daniel Butler, Micheal McKenna, Jem Chalk, Layla Lavallee, Elizabeth Hadley, Lucy Cureton, Magdalena Benysek, Monique Andersson, Maria Coates, Sarah Barrett, Clare Bateman, Jennifer C Davies, Ivy Raymundo-Wood, Andrew Ustianowski, Andrew Carson-Stevens, Ly-Mee Yu, Paul Little, Akosua A Agyeman, Tanveer Ahmed, Damien Allcock, Adrian Beltran-Martinez, Oluseye E Benedict, Nigel Bird, Laura Brennan, Julianne Brown, Gerard Burns, Mike Butler, Zelda Cheng, Ruth Danson, Nigel de Kare-Silver, Devesh Dhasmana, Jon Dickson, Serge Engamba, Stacey Fisher, Robin Fox, Eve Frost, Richard Gaunt, Sarit Ghosh, Ishtiaq Gilkar, Anna Goodman, Steve Granier, Aleksandra Howell, Iqbal Hussain, Simon Hutchinson, Marie Imlach, Greg Irving, Nicholas Jacobsen, James Kennard, Umar Khan, Kyle Knox, Christopher Krasucki, Tom Law, Rem Lee, Nicola Lester, David Lewis, James Lunn, Claire I. Mackintosh, Mehul Mathukia, Patrick Moore, Seb Morton, Daniel Murphy, Rhiannon Nally, Chinonso Ndukauba, Olufunto Ogundapo, Henry Okeke, Amit Patel, Kavil Patel, Ruth Penfold, Satveer Poonian, Olajide Popoola, Alexander Pora, Vibhore Prasad, Rishabh Prasad, Omair Razzaq, Scot Richardson, Simon Royal, Afsana Safa, Satash Sehdev, Tamsin Sevenoaks, Divya Shah, Aadil Sheikh, Vanessa Short, Baljinder S Sidhu, Ivor Singh, Yusuf Soni, Chris Thalasselis, Pete Wilson, David Wingfield, Michael Wong, Maximillian N J Woodall, Nick Wooding, Sharon Woods, Joanna Yong, Francis Yongblah, Azhar Zafar, University of St Andrews. School of Medicine, and Group, PANORAMIC Trial Collaborative
- Subjects
anti-viral ,Medicine(all) ,Adult ,MCC ,COVID-19 Vaccines ,SARS-CoV-2 ,COVID-19 ,Bayes Theorem ,General Medicine ,3rd-DAS ,Middle Aged ,Treatment Outcome ,SDG 3 - Good Health and Well-being ,RA0421 ,Virology ,RA0421 Public health. Hygiene. Preventive Medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,Family Practice - Abstract
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the community at increased risk of morbidity and mortality from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care reduced hospital admissions and deaths associated with COVID-19 in this population. Methods PANORAMIC was a UK-based, national, multicentre, open-label, multigroup, prospective, platform adaptive randomised controlled trial. Eligible participants were aged 50 years or older—or aged 18 years or older with relevant comorbidities—and had been unwell with confirmed COVID-19 for 5 days or fewer in the community. Participants were randomly assigned (1:1) to receive 800 mg molnupiravir twice daily for 5 days plus usual care or usual care only. A secure, web-based system (Spinnaker) was used for randomisation, which was stratified by age (vs ≥50 years) and vaccination status (yes vs no). COVID-19 outcomes were tracked via a self-completed online daily diary for 28 days after randomisation. The primary outcome was all-cause hospitalisation or death within 28 days of randomisation, which was analysed using Bayesian models in all eligible participants who were randomly assigned. This trial is registered with ISRCTN, number 30448031. Findings Between Dec 8, 2021, and April 27, 2022, 26 411 participants were randomly assigned, 12 821 to molnupiravir plus usual care, 12 962 to usual care alone, and 628 to other treatment groups (which will be reported separately). 12 529 participants from the molnupiravir plus usual care group, and 12 525 from the usual care group were included in the primary analysis population. The mean age of the population was 56·6 years (SD 12·6), and 24 290 (94%) of 25 708 participants had had at least three doses of a SARS-CoV-2 vaccine. Hospitalisations or deaths were recorded in 105 (1%) of 12 529 participants in the molnupiravir plus usual care group versus 98 (1%) of 12 525 in the usual care group (adjusted odds ratio 1·06 [95% Bayesian credible interval 0·81–1·41]; probability of superiority 0·33). There was no evidence of treatment interaction between subgroups. Serious adverse events were recorded for 50 (0·4%) of 12 774 participants in the molnupiravir plus usual care group and for 45 (0·3%) of 12 934 in the usual care group. None of these events were judged to be related to molnupiravir. Interpretation Molnupiravir did not reduce the frequency of COVID-19-associated hospitalisations or death among high-risk vaccinated adults in the community. Funding UK National Institute for Health and Care Research
- Published
- 2023
35. Defining Environmental Health Literacy
- Author
-
Hoover, Anna Goodman, primary
- Published
- 2018
- Full Text
- View/download PDF
36. Inpatient COVID-19 vaccination rollout: Improving access to vaccination
- Author
-
Tanveer Bawa, Dylan Smith, Daria Andreeva, Smitkumar Vaidya, Besmira Kruja, Tegan Farrell, Agata Ziemba, Clare Jones, Alexandra Travers, Andrew Guilder, Tiago Rua, Nigel Beckett, Ali Hashtroudi, Claire Mallinson, and Anna Goodman
- Subjects
Inpatients ,COVID-19 Vaccines ,Vaccination ,Humans ,COVID-19 ,General Medicine ,Quality Improvement - Abstract
BACKGROUND: We were aware of high numbers of inpatients unvaccinated against COVID-19 at Guy's and St Thomas' NHS Foundation Trust (GSTT). Due to this, an inpatient vaccination protocol was set up in July 2021, with initially limited uptake. METHODS: From October 2021, a multidisciplinary team worked to improve the protocol for inpatient vaccination, with the development of a system that gave ownership to clinical teams. RESULTS: In 4 months (July 2021 to November 2021), 20 inpatients had been vaccinated at GSTT. Following our intervention, rates of uptake increased, and 34 patients were vaccinated in less than 2 months (November 2021 to January 2022). Forty-five patients who had been referred were discharged without vaccination; attempts were made to invite them to receive a vaccine. CONCLUSION: An improved pathway and referral process increased the number of inpatient vaccinations delivered. Further work is required in order to ensure that more patients who have been referred are vaccinated.
- Published
- 2022
37. Evolving role of novel COVID-19 Medicine Delivery Units
- Author
-
Alice Packham, Niamh Spence, and Anna Goodman
- Subjects
Rehabilitation ,Physical Therapy, Sports Therapy and Rehabilitation ,General Medicine - Published
- 2022
38. Clinical features and management of human monkeypox: a retrospective observational study in the UK
- Author
-
Hugh Adler, Susan Gould, Paul Hine, Luke B Snell, Waison Wong, Catherine F Houlihan, Jane C Osborne, Tommy Rampling, Mike BJ Beadsworth, Christopher JA Duncan, Jake Dunning, Tom E Fletcher, Ewan R Hunter, Michael Jacobs, Saye H Khoo, William Newsholme, David Porter, Robert J Porter, Libuše Ratcliffe, Matthias L Schmid, Malcolm G Semple, Anne J Tunbridge, Tom Wingfield, Nicholas M Price, Mike Abouyannis, Asma Al-Balushi, Stephen Aston, Robert Ball, Nicholas J Beeching, Thomas J Blanchard, Ffion Carlin, Geraint Davies, Angela Gillespie, Scott R Hicks, Marie-Claire Hoyle, Chinenye Ilozue, Luke Mair, Suzanne Marshall, Anne Neary, Emmanuel Nsutebu, Samantha Parker, Hannah Ryan, Lance Turtle, Chris Smith, Jon van Aartsen, Naomi F Walker, Stephen Woolley, Anu Chawla, Ian Hart, Anna Smielewska, Elizabeth Joekes, Cathryn Benson, Cheryl Brindley, Urmi Das, Chin K Eyton-Chong, Claire Gnanalingham, Clare Halfhide, Beatriz Larru, Sarah Mayell, Joanna McBride, Claire Oliver, Princy Paul, Andrew Riordan, Lekha Sridhar, Megan Storey, Audrey Abdul, Jennifer Abrahamsen, Breda Athan, Sanjay Bhagani, Colin S Brown, Oliver Carpenter, Ian Cropley, Kerrie Frost, Susan Hopkins, Jessica Joyce, Lucy Lamb, Adrian Lyons, Tabitha Mahungu, Stephen Mepham, Edina Mukwaira, Alison Rodger, Caroline Taylor, Simon Warren, Alan Williams, Debbie Levitt, Denise Allen, Jill Dixon, Adam Evans, Pauline McNicholas, Brendan Payne, D Ashley Price, Uli Schwab, Allison Sykes, Yusri Taha, Margaret Ward, Marieke Emonts, Stephen Owens, Alina Botgros, Sam T Douthwaite, Anna Goodman, Akish Luintel, Eithne MacMahon, Gaia Nebbia, Geraldine O'Hara, Joseph Parsons, Ashwin Sen, Daniel Stevenson, Tadgh Sullivan, Usman Taj, Claire van Nipsen tot Pannerden, Helen Winslow, Ewa Zatyka, Ekene Alozie-Otuka, Csaba Beviz, Yusupha Ceesay, Latchmin Gargee, Morloh Kabia, Hannah Mitchell, Shona Perkins, Mingaile Sasson, Kamal Sehmbey, Federico Tabios, Neil Wigglesworth, Emma J Aarons, Tim Brooks, Matthew Dryden, Jenna Furneaux, Barry Gibney, Jennifer Small, Elizabeth Truelove, Clare E Warrell, Richard Firth, Gemma Hobson, Christopher Johnson, Alison Dewynter, Sebastian Nixon, Oliver Spence, Joachim J Bugert, Dennis E Hruby, and Network, NHS England High Consequence Infectious Diseases (Airborne)
- Subjects
Adult ,Male ,Infectious Diseases ,Animals ,Humans ,Female ,Monkeypox ,Prospective Studies ,Child ,Antiviral Agents ,United Kingdom ,Retrospective Studies - Abstract
Background Cases of human monkeypox are rarely seen outside of west and central Africa. There are few data regarding viral kinetics or the duration of viral shedding and no licensed treatments. Two oral drugs, brincidofovir and tecovirimat, have been approved for treatment of smallpox and have demonstrated efficacy against monkeypox in animals. Our aim was to describe the longitudinal clinical course of monkeypox in a high-income setting, coupled with viral dynamics, and any adverse events related to novel antiviral therapies. Methods In this retrospective observational study, we report the clinical features, longitudinal virological findings, and response to off-label antivirals in seven patients with monkeypox who were diagnosed in the UK between 2018 and 2021, identified through retrospective case-note review. This study included all patients who were managed in dedicated high consequence infectious diseases (HCID) centres in Liverpool, London, and Newcastle, coordinated via a national HCID network. Findings We reviewed all cases since the inception of the HCID (airborne) network between Aug 15, 2018, and Sept 10, 2021, identifying seven patients. Of the seven patients, four were men and three were women. Three acquired monkeypox in the UK: one patient was a health-care worker who acquired the virus nosocomially, and one patient who acquired the virus abroad transmitted it to an adult and child within their household cluster. Notable disease features included viraemia, prolonged monkeypox virus DNA detection in upper respiratory tract swabs, reactive low mood, and one patient had a monkeypox virus PCR-positive deep tissue abscess. Five patients spent more than 3 weeks (range 22–39 days) in isolation due to prolonged PCR positivity. Three patients were treated with brincidofovir (200 mg once a week orally), all of whom developed elevated liver enzymes resulting in cessation of therapy. One patient was treated with tecovirimat (600 mg twice daily for 2 weeks orally), experienced no adverse effects, and had a shorter duration of viral shedding and illness (10 days hospitalisation) compared with the other six patients. One patient experienced a mild relapse 6 weeks after hospital discharge. Interpretation Human monkeypox poses unique challenges, even to well resourced health-care systems with HCID networks. Prolonged upper respiratory tract viral DNA shedding after skin lesion resolution challenged current infection prevention and control guidance. There is an urgent need for prospective studies of antivirals for this disease.
- Published
- 2022
39. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO):a randomised controlled trial
- Author
-
Wesley H. Self, Uriel Sandkovsky, Cavan S. Reilly, David M. Vock, Robert L. Gottlieb, Michael Mack, Kevin Golden, Emma Dishner, Andrew Vekstein, Emily R. Ko, Tatyana Der, John Franzone, Eyad Almasri, Mohamed Fayed, Michael R. Filbin, Kathryn A. Hibbert, Todd W. Rice, Jonathan D. Casey, J. Awori Hayanga, Vinay Badhwar, Bradley G. Leshnower, Milad Sharifpour, Kirk U. Knowlton, Ithan D. Peltan, Elizieta Bakowska, Justyna Kowalska, Michael E. Bowdish, Jeffrey M. Sturek, Angela J. Rogers, D. Clark Files, Jarrod M. Mosier, Michelle N. Gong, David J. Douin, R. Duncan Hite, Barbara W. Trautner, Mamta K. Jain, Edward M. Gardner, Akram Khan, Jens-Ulrik Jensen, Michael A. Matthay, Adit A. Ginde, Samuel M. Brown, Elizabeth S. Higgs, Sarah Pett, Amy C. Weintrob, Christina C. Chang, Daniel D. Murrary, Huldrych F. Günthard, Ellen Moquete, Greg Grandits, Nicole Engen, Birgit Grund, Shweta Sharma, Huyen Cao, Rajesh Gupta, Suzette Osei, David Margolis, Qing Zhu, Mark N. Polizzotto, Abdel G. Babiker, Victoria J. Davey, Virginia Kan, B. Taylor Thompson, Annetine C. Gelijns, James D. Neaton, H. Clifford Lane, Jens D. Jundgren, John Tierney, Kevin Barrett, Betsey R. Herpin, Mary C. Smolskis, Susan E. Voge, Laura A. McNay, Kelly Cahill, Page Crew, Matthew Kirchoff, Ratna Sardana, Sharon Segal Raim, Joseph Chiu, Lisa Hensley, Josua Lorenzo, Rebecca Mock, Katy Shaw-Saliba, Judith Zuckerman, Stacey J. Adam, Judy Currier, Sarah Read, Eric Hughes, Laura Amos, Amy Carlsen, Anita Carter, Bionca Davis, Eileen Denning, Alain DuChene, Merrie Harrison, Payton Kaiser, Joseph Koopmeiners, Sue Meger, Thomas Murray, Kien Quan, Siu Fun Quan, Greg Thompson, Jamie Walski, Deborah Wentworth, Alan J. Moskowitz, Emilia Bagiella, Karen O'Sullivan, Mary E. Marks, Evan Accardi, Emily Kinzel, Gabriela Bedoya, Lopa Gupta, Jessica R. Overbey, Maria L. Padillia, Milerva Santos, Marc A. Gillinov, Marissa A. Miller, Wendy C. Taddei-Peters, Kathleen Fenton, Mezgebe Berhe, Clinton Haley, Christopher Bettacchi, Erin Duhaime, Madison Ryan, Sarah Burris, Felecia Jones, Samantha Villa, Samantha Want, Raven Robert, Tanquinisha Coleman, Laura Clariday, Rebecca Baker, Marian Hurutado-Rodriguez, Nazia Iram, Michelle Fresnedo, Allyson Davis, Kiara Leonard, Noelia Ramierez, Jon Thammavong, Krizia Duque, Emma Turner, Tammy Fisher, Dianna Robinson, Desirae Ransom, Erica Lusk, Aaron Killian, Adriana Palacious, Edilia Solis, Janet Jerrow, Matthew Watts, Heather Whitacre, Elizabeth Cothran, Peter K. Smith, Christina E. Barkauskas, Grace R. Dreyer, Marie Witte, Nilima Mosaly, Ahmad Mourad, Thomas L. Holland, Kathleen Lane, Andrew Bouffler, Lauren M. McGowan, Marry Motta, Gregory Tipton, Ben Stallings, Gennifer Stout, Beth McLendon-Arvik, Beth A. Hollister, Dana M. Giangiacomo, Sunil Sharma, Brian Pappers, Paul McCarthy, Troy Krupica, Arif Sarwari, Rebecca Reece, Lisa Fornaresio, Chad Glaze, Raquel Evans, Katarina Preamble, Lisa Giblin Sutton, Sabrina Buterbaugh, Elizabeth Berry Bartolo, Roger Williams, Robin Bunner, William Bender, Jeffrey Miller, Kim T. Baio, Mary K. McBride, Michele Fielding, Sonya Mathewson, Kristina Porte, Missy Maton, Chari Ponder, Elizabeth Haley, Christine Spainhour, Susan Rogers, Derrick Tyler, Noah Wald-Dickler, Douglass Hutcheon, Amytis Towfighi, May M. Lee, Meghan R. Lewis, Brad Spellberg, Linda Sher, Aniket Sharma, Anna P. Olds, Chris Justino, Edward Lozano, Chris Romero, Janet Leong, Valentina Rodina, Tammie Possemato, Jose Escobar, Charlene Chiu, Kevin Weissman, Andrew Barros, Kyle B. Enfield, Alexandra Kadl, China J. Green, Rachel M. Simon, Ashley Fox, Kara Thornton, Patrick E. Parrino, Stephen Spindel, Aditya Bansal, Katherine Baumgarten, Jonathan Hand, Derek Vonderhaar, Bobby Nossaman, Sylvia Laudun, DeAnna Ames, Shane Broussard, Nilmo Hernandez, Geralyn Isaac, Huan Dinh, Yiling Zheng, Sonny Tran, Hunter McDaniel, Nicolle Crovetto, Leslie Miller, Beth Schelle, Sherry McLean, Howard R. Rothbaum, Michael S. Alvarez, Shivam P. Kalan, Heather H. Germann, Jennifer Hendershot, Karen Maroney, Karen Herring, Sharri Cook, Pam Paul, Ronson J. Madathil, Joseph Rabin, Andrea Levine, Kapil Saharia, Ali Tabatabai, Christine Lau, James S. Gammie, Maya-Loren Peguero, Kimberley McKernan, Matthew Audette, Emily Fleischmann, Freshta Akbari, Maia Lee, Myounghee Lee, Andrew Chi, Hanna Salehi, Alan Pariser, Phuong Tran Nguyen, Jessica Moore, Adrienne Gee, Shelika Vincent, Richard A. Zuckerman, Alexander Iribarne, Sara Metzler, Samantha Shipman, Taylor Caccia, Haley Johnson, Crystallee Newton, Doug Parr, Vicente Rodriguez, Gordon Bokhart, Sharon M. Eichman, Crystal North, Cathryn Oldmixon, Nancy Ringwood, Laura Fitzgerald, Haley D. Morin, Ariela Muzikansky, Richard Morse, Roy G. Brower, Lora A. Reineck, Neil R. Aggarwal, Karen Bienstock, Peter Hou, Jay Steingrub, Mark A. Tidswell, Lori-Ann Kozikowski, Cynthia Kardos, Leslie DeSouza, Sherell Thornton-Thompson, Daniel Talmor, Nathan Shapiro, Valerie Banner-Goodspeed, Katherine L. Boyle, Sharon Hayes, Alan E. Jones, James Galbraith, Utsav Nandi, Rebekah K. Peacock, Blair Alden Parry, Justin D. Margolin, Kelsey Brait, Caroline Beakes, Kirsten N. Kangelaris, Kimberly J. Yee, Kimia Ashktorab, Alejandra E. Jauregui, Hanjing Zhuo, Gregory Hendey, Kinsley A. Hubel, Alyssa R. Hughes, Rebekah L. Garcia, Jennifer G. Wilson, Rosemary Vojnik, Jonasel Roque, Cynthia Perez, George W. Lim, Steven Y. Chang, Rebecca Beutler, Trisha Agarwal, Julia Vargas, Marc Moss, Amiran Baduashvili, Lakshmi Chauhan, Lani L. Finck, Michelle Howell, Robert C. Hyzy, Pauline K. Park, Kristine Nelson, Jake I. McSparron, Ivan N. Co, Bonnie R. Wang, Shijing Jia, Barbara Sullins, Sinan Hanna, Norman Olbrich, Lynne D. Richardson, Rahul Nair, Obiageli Offor, Brenda Lopez, Omowunmi Amosu, Hiwet Tzehaie, Thomas E. Terndrup, Herbert P. Wiedemann, Abhijit Duggal, Nirosshan Thiruchelvam, Kiran Ashok, Alexander H. King, Omar Mehkri, Kristin Hudock, Simra Kiran, Harshada More, Tammy Roads, Jamie Martinkovic, Sarah Kennedy, Bryce H. Robinson, Catherine L. Hough, Olivia F. Krol, Mistry Kinjal, Emmanuel Mills, Madeline McDougal, Rupali Deshmukh, Peter Chen, Sam S. Torbati, Yuri Matusov, June Choe, Niree A. Hindoyan, Susan E. Jackman, Emad Bayoumi, Timothy Wynter, Antonina Caudill, Ethan Pascual, Gregg J. Clapham, Lisa Herrera, Cristabelle Ojukwu, Shaunt Mehdikhani, D. Shane O'Mahony, Sonam T. Nyatsatsang, David M. Wilson, Julie A. Wallick, Chadwick Miller, Keven W. Gibbs, Lori S. Flores, Mary E. LaRose, Leigha D. Landreth, Peter E. Morris, Jamie L. Sturgill, Evan P. Cassity, Sanjay Dhar, Ashley A. Montgomery-Yates, Sara N. Pasha, Kirby P. Mayer, Brittany Bissel, Joseph Bledsoe, Samuel Brown, Michael Lanspa, Lindsey Leither, Brent P. Armbruster, Quinn Montgomery, Darrin Applegate, Naresh Kumar, Melissa Fergus, Erna Serezlic, Karah Imel, Ghazal Palmer, Brandon Webb, Valerie T. Aston, Jakea Johnson, Christopher Gray, Margaret Hays, Megan Roth, Adriana Sánchez, Laura Popielski, Heather Rivasplata, Melissa Turner, Michael Vjecha, Tianna Petersen, Dena Kamel, Laura Hansen, Claudia Sanchez Lucas, Natalie DellaValle, Sonia Gonzales, James Scott, David Wyles, Ivor Douglas, Jason Haukoos, Kevin Kamis, Caitlin Robinson, Jason V. Baker, Anne Frosch, Rachael Goldsmith, Hodan Jibrell, Melanie Lo, Jonathan Klaphake, Shari Mackedanz, Linh Ngo, Kelly Garcia-Myers, Norman Markowitz, Erika Pastor, Mayur Ramesh, Indira Brar, Emanuel Rivers, Princy Kumar, Maximiliano Menna, Kousick Biswas, Cristin Harrington, Alex Delp, Lavannya Pandit, Casey Hines-Munson, John Van, Laura Dillon, Yiqun Want, Paola Lichtenberger, Gio Baracco, Carol Ramos, Lauren Bjork, Melyssa Sueiro, Phyllis Tien, Heather Freasier, Theresa Buck, Hafida Nekach, Stephanie Nagy-Agren, Shikha Vasudeva, Tracy Ochalek, Brentin Roller, Chinh Nguyen, Amani Mikail, Dorthe Raben, Tomas O. Jensen, Bitten Aagaard, Charlotte B. Nielsen, Katharina Krapp, Bente Rosdahl Nykjær, Katja Lisa Kanne, Anne Louise Grevsen, Zillah Maria Joensen, Tina Bruun, Ane Bojesen, Frederik Woldbye, Nick E. Normand, Frederik V.L. Esmann, Clara Lundetoft Clausen, Nichlas Hovmand, Karen Brorup Pedersen, Louise Thorlacius-Ussing, Michaela Tinggaard, Dorthe S. Høgsberg, Ema Rastoder, Thobias Kamstrup, Christina Marisa Bergsøe, Lars Østergaard, Nina Breinholt Stærke, Isik S. Johansen, Fredrikke C. Knudtzen, Lykke Larsen, Mathias A. Hertz, Thilde Fabricius, Marie Helleberg, Jan Gerstoft, Tomas Østergaard Jensen, Birgitte Lindegaard, Thomas Ingemann Pedersen, Birgit Thorup Røge, Sandra Valborg Løfberg, Thomas Michael Hansen, Ariella Denize Nielsen, Sebastian Leicht von Huth, Henrik Nielsen, Rikke Krog Thisted, Daria Podlekareva, Stine Johnsen, Helle Frost Andreassen, Lars Pedersen, Cecilia Ebba Clara Ellinor Lindnér, Lothar Wiese, Lene Surland Knudsen, Nikolaj Julian Skrøder Nytofte, Signe Ravn Havmøller, Roger Paredes, Maria Exposito, Eduardo Fernández-Cruz, José Muñoz, Jose R. Arribas, Vicente Estrada, Juan P. Horcajada, Joaquin Burgos, Jose Luis Morales-Rull, Dominique L. Braun, Emily West, Khadija M'Rabeth-Bensalah, Mareile L. Eichinger, Manuela Grüttner-Durmaz, Christina Grube, Veronika Zink, Andrzej Horban, Agnieszka Bednarska, Natalia Jurek, Gerd Fätkenheuer, Jakob J. Malinm, Gail Matthews, Anthony Kelleher, Gesalit Cabrera, Catherine Carey, Sally Hough, Sophie Virachit, Amy Zhong, Barnaby E. Young, Po Ying Chia, Tau Hong Lee, Ray J. Lin, David Lye, Sean Ong, Ser Hon Puah, Tsin Wen Yeo, Shiau Hui Diong, Juwinda Ongko, Fleur Hudson, Mahesh KB Parmar, Anna Goodman, Jonathan Badrock, Adam Gregory, Nicola Harris, Giota Touloumi, Nikos Pantaz, Vicky Gioukari, Joseph Lutaakome, Cissy M. Kityo, Henry Mugerwa, Francis Kiweewa, Anu Osinusi, Craig Tipple, Angela Willis, Amanda Peppercorn, Helen Watson, Elizabeth Alexander, Erik Mogalian, Leo Lin, Xiao Ding, Li Yan, Jean-Luc Girardet, Ji Ma, Zhi Hong, Amy Adams, Sara Albert, Abby Balde, Michelle Baracz, Beth Baseler, Nancy Becker, Mona Bielica, Shere Billouin-Frazier, Jennifer Cash, Jay Choudhary, Suzanne Dolney, Mary Dixon, Carolyn Eyler, Leanna Frye, Michael Galcik, Jensen Gertz, Lisa Giebeig, Neelam Gulati, Liz Hankinson, Debbie Hissey, Debi Hogarty, Matt Hohn, H Preston Holley, Lisa Hoopengardner, Lynda Huber, Shirley Jankelevich, Gary Krauss, Eileen Lake, Jessica Linton, Leah MacDonald, Meryan Manandhar, Mary Spinelli-Nadzam, Charles Oluremi, Calvin Proffitt, Erin Rudzinski, Jen Sandrus, Marylu Schaffhauser, Adam Schechner, Connie Suders, Norman P. Gerry, Kenneth Smith, Courtney Solomon, Amanda Kubernac, Marium Rashid, Bhakti Patel, Robert Kubernac, Joseph Murphy, Marie L. Hoover, Craig Brown, Nadine DuChateau, Adam Flosi, Les Johnson, Amy Treagus, and Christine Wenner
- Subjects
Adult ,Male ,Adolescent ,SARS-CoV-2 ,Comment ,COVID-19 ,Antibodies, Monoclonal ,Articles ,Middle Aged ,Antibodies, Monoclonal, Humanized ,Antibodies, Neutralizing ,COVID-19/drug therapy ,COVID-19 Drug Treatment ,Hospitalization ,Infectious Diseases ,Antineoplastic Agents, Immunological ,Treatment Outcome ,Antibodies, Monoclonal, Humanized/therapeutic use ,Double-Blind Method ,Humans ,Female ,Aged - Abstract
BACKGROUND: We aimed to assess the efficacy and safety of two neutralising monoclonal antibody therapies (sotrovimab [Vir Biotechnology and GlaxoSmithKline] and BRII-196 plus BRII-198 [Brii Biosciences]) for adults admitted to hospital for COVID-19 (hereafter referred to as hospitalised) with COVID-19.METHODS: In this multinational, double-blind, randomised, placebo-controlled, clinical trial (Therapeutics for Inpatients with COVID-19 [TICO]), adults (aged ≥18 years) hospitalised with COVID-19 at 43 hospitals in the USA, Denmark, Switzerland, and Poland were recruited. Patients were eligible if they had laboratory-confirmed SARS-CoV-2 infection and COVID-19 symptoms for up to 12 days. Using a web-based application, participants were randomly assigned (2:1:2:1), stratified by trial site pharmacy, to sotrovimab 500 mg, matching placebo for sotrovimab, BRII-196 1000 mg plus BRII-198 1000 mg, or matching placebo for BRII-196 plus BRII-198, in addition to standard of care. Each study product was administered as a single dose given intravenously over 60 min. The concurrent placebo groups were pooled for analyses. The primary outcome was time to sustained clinical recovery, defined as discharge from the hospital to home and remaining at home for 14 consecutive days, up to day 90 after randomisation. Interim futility analyses were based on two seven-category ordinal outcome scales on day 5 that measured pulmonary status and extrapulmonary complications of COVID-19. The safety outcome was a composite of death, serious adverse events, incident organ failure, and serious coinfection up to day 90 after randomisation. Efficacy and safety outcomes were assessed in the modified intention-to-treat population, defined as all patients randomly assigned to treatment who started the study infusion. This study is registered with ClinicalTrials.gov, NCT04501978.FINDINGS: Between Dec 16, 2020, and March 1, 2021, 546 patients were enrolled and randomly assigned to sotrovimab (n=184), BRII-196 plus BRII-198 (n=183), or placebo (n=179), of whom 536 received part or all of their assigned study drug (sotrovimab n=182, BRII-196 plus BRII-198 n=176, or placebo n=178; median age of 60 years [IQR 50-72], 228 [43%] patients were female and 308 [57%] were male). At this point, enrolment was halted on the basis of the interim futility analysis. At day 5, neither the sotrovimab group nor the BRII-196 plus BRII-198 group had significantly higher odds of more favourable outcomes than the placebo group on either the pulmonary scale (adjusted odds ratio sotrovimab 1·07 [95% CI 0·74-1·56]; BRII-196 plus BRII-198 0·98 [95% CI 0·67-1·43]) or the pulmonary-plus complications scale (sotrovimab 1·08 [0·74-1·58]; BRII-196 plus BRII-198 1·00 [0·68-1·46]). By day 90, sustained clinical recovery was seen in 151 (85%) patients in the placebo group compared with 160 (88%) in the sotrovimab group (adjusted rate ratio 1·12 [95% CI 0·91-1·37]) and 155 (88%) in the BRII-196 plus BRII-198 group (1·08 [0·88-1·32]). The composite safety outcome up to day 90 was met by 48 (27%) patients in the placebo group, 42 (23%) in the sotrovimab group, and 45 (26%) in the BRII-196 plus BRII-198 group. 13 (7%) patients in the placebo group, 14 (8%) in the sotrovimab group, and 15 (9%) in the BRII-196 plus BRII-198 group died up to day 90.INTERPRETATION: Neither sotrovimab nor BRII-196 plus BRII-198 showed efficacy for improving clinical outcomes among adults hospitalised with COVID-19.FUNDING: US National Institutes of Health and Operation Warp Speed.
- Published
- 2022
40. Measuring Your Impact on Loneliness in Later Life
- Author
-
Anna Goodman and Anna Goodman
- Abstract
What does this guidance cover?Are you working to prevent or reduce loneliness in your community? Can you articulate the difference you are making to the lives of older people?We're all working in an increasingly competitive funding environment, and we all need to be able to demonstrate robustly that we make a difference. Funders across the public, voluntery and private sectors also face their own financial pressures and need evidence that the programmes they fund are delivering real change for the people they support.This guidance offers information and advice on choosing and using a scale to measure the impact of your services on loneliness in older age.
- Published
- 2022
41. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children
- Author
-
Anna, Turkova, Ellen, White, Hilda A, Mujuru, Adeodata R, Kekitiinwa, Cissy M, Kityo, Avy, Violari, Abbas, Lugemwa, Tim R, Cressey, Philippa, Musoke, Ebrahim, Variava, Mark F, Cotton, Moherndran, Archary, Thanyawee, Puthanakit, Osee, Behuhuma, Robin, Kobbe, Steven B, Welch, Mutsa, Bwakura-Dangarembizi, Pauline, Amuge, Elizabeth, Kaudha, Linda, Barlow-Mosha, Shafic, Makumbi, Nastassja, Ramsagar, Chaiwat, Ngampiyaskul, Godfrey, Musoro, Lorna, Atwine, Afaaf, Liberty, Victor, Musiime, Dickson, Bbuye, Grace M, Ahimbisibwe, Suwalai, Chalermpantmetagul, Shabinah, Ali, Tatiana, Sarfati, Ben, Wynne, Clare, Shakeshaft, Angela, Colbers, Nigel, Klein, Sarah, Bernays, Yacine, Saïdi, Alexandra, Coelho, Tiziana, Grossele, Alexandra, Compagnucci, Carlo, Giaquinto, Pablo, Rojo, Deborah, Ford, Diana M, Gibb, and Anna, Goodman
- Subjects
Oral ,Cyclopropanes ,Male ,Adolescent ,Pyridones ,Administration, Oral ,HIV Infections ,3-Ring ,Article ,Piperazines ,Drug Therapy ,Heterocyclic Compounds ,Oxazines ,Humans ,HIV Integrase Inhibitors ,Child ,Preschool ,Alkynes ,Anti-Retroviral Agents ,Benzoxazines ,Child, Preschool ,Cholesterol ,Drug Therapy, Combination ,Female ,HIV Protease Inhibitors ,Heterocyclic Compounds, 3-Ring ,Viral Load ,HIV-1 ,General Medicine ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Administration ,Combination - Abstract
Item does not contain fulltext BACKGROUND: Children with human immunodeficiency virus type 1 (HIV-1) infection have limited options for effective antiretroviral treatment (ART). METHODS: We conducted an open-label, randomized, noninferiority trial comparing three-drug ART based on the HIV integrase inhibitor dolutegravir with standard care (non-dolutegravir-based ART) in children and adolescents starting first- or second-line ART. The primary end point was the proportion of participants with virologic or clinical treatment failure by 96 weeks, as estimated by the Kaplan-Meier method. Safety was assessed. RESULTS: From September 2016 through June 2018, a total of 707 children and adolescents who weighed at least 14 kg were randomly assigned to receive dolutegravir-based ART (350 participants) or standard care (357). The median age was 12.2 years (range, 2.9 to 18.0), the median weight was 30.7 kg (range, 14.0 to 85.0), and 49% of the participants were girls. By design, 311 participants (44%) started first-line ART (with 92% of those in the standard-care group receiving efavirenz-based ART), and 396 (56%) started second-line ART (with 98% of those in the standard-care group receiving boosted protease inhibitor-based ART). The median follow-up was 142 weeks. By 96 weeks, 47 participants in the dolutegravir group and 75 in the standard-care group had treatment failure (estimated probability, 0.14 vs. 0.22; difference, -0.08; 95% confidence interval, -0.14 to -0.03; P = 0.004). Treatment effects were similar with first- and second-line therapies (P = 0.16 for heterogeneity). A total of 35 participants in the dolutegravir group and 40 in the standard-care group had at least one serious adverse event (P = 0.53), and 73 and 86, respectively, had at least one adverse event of grade 3 or higher (P = 0.24). At least one ART-modifying adverse event occurred in 5 participants in the dolutegravir group and in 17 in the standard-care group (P = 0.01). CONCLUSIONS: In this trial involving children and adolescents with HIV-1 infection who were starting first- or second-line treatment, dolutegravir-based ART was superior to standard care. (Funded by ViiV Healthcare; ODYSSEY ClinicalTrials.gov number, NCT02259127; EUDRACT number, 2014-002632-14; and ISRCTN number, ISRCTN91737921.).
- Published
- 2021
42. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
- Author
-
Pauline Amuge, Abbas Lugemwa, Ben Wynne, Hilda A Mujuru, Avy Violari, Cissy M Kityo, Moherndran Archary, Ebrahim Variava, Ellen White, Rebecca M Turner, Clare Shakeshaft, Shabinah Ali, Kusum J Nathoo, Lorna Atwine, Afaaf Liberty, Dickson Bbuye, Elizabeth Kaudha, Rosie Mngqibisa, Modehei Mosala, Vivian Mumbiro, Annet Nanduudu, Rogers Ankunda, Lindiwe Maseko, Adeodata R Kekitiinwa, Carlo Giaquinto, Pablo Rojo, Diana M Gibb, Anna Turkova, Deborah Ford, Amina Farhana Mehar (nee Abdulla), Pattamukkil Abraham, Elaine Abrams, Judith Acero, Gerald Muzorah Agaba, Grace Ahimbisibwe, Barbara Ainebyoona, Winnie Akobye, Yasmeen Akhalwaya, Nazim Akoojee, Shabinah S. Ali, Catherine Andrea, Maria Angeles Muñoz Fernandez, Diana Antonia Rutebarika, Suvaporn Anugulruengkitt, Tsitsi Apollo, Ronelle Arendze, Juliet Ategeka, Eunice Atim, Abdel Babiker, Sarah Babirye, Enock Babu, Edward Bagirigomwa, Angella Baita, David Balamusani, Patsy Baliram, David Baliruno, Colin Ball, Henry Balwa, Alasdair Bamford, Srini Bandi, Dominique Barker, Linda Barlow-Mosha, Shazia Begum, Osee Behuhuma, Sarah Bernays, Rogers Besigye, Maria Bester, Joyline Bhiri, Davide Bilardi, Kristien Bird, Pauline Bollen, Chiara Borg, Anne-Marie Borges Da Silva, Jackie Brown, Elena Bruno, Torsak Bunupuradah, David Burger, Nomzamo Buthelezi, Mutsa Bwakura-Dangarembizi, Africanus Byaruhanga, Joanna Calvert, Petronelle Casey, Haseena Cassim, Sphiwee Cebekhulu, Sanuphong Chailert, Suwalai Chalermpantmetagul, Wanna Chamjamrat, Man Chan, Precious Chandiwana, Thannapat Chankun, Sararut Chanthaburanun, Nuttawut Chanto, Ennie Chidziva, Minenhle Chikowore, Joy Chimanzi, Dujrudee Chinwong, Stuart Chitongo, Moses Chitsamatanga, Joshua Choga, Duangrat Chutima, Polly Clayden, Alexandra Coelho, Angela Colbers, Alexandra Compagnucci, Ana Constança Mendes, Magda Conway, Mark F. Cotton, Jane Crawley, Tim R. Cressey, Jacky Crisp, Ana Cristina Matos, Sumaya Dadan, Jacqui Daglish, Siva Danaviah, Tseleng Daniel, Anita De Rossi, Sukanda Denjanta, Els Dobbels, Maria Dowie, Prosper Dube, Benedictor Dube, Nimisha Dudakia, Alice Elwana, Cristina Epalza, David Eram, Juan Erasmus, Peter Erim, Luis Escosa Garcia, Zaakirah Essack, Carolina Estepa, Monica Etima, Alexandre Fernandes, Maite Fernandez, Felicity Fitzgerald, Jacquie Flynn, Claudia Fortuny Guasch, Caroline Foster, George Fourie, Yolandie Fourie, Sophie Foxall, Derusha Frank, Kate Gandhi, India Garcia, Kathleen Gartner, Joshua Gasa, Gugu Gasa, Diana M. Gibb, Coral Gomez Rico, Daniel Gomez-Pena, Secrecy Gondo, Anna Goodman, Maria Gorreti Nakalema, Winnie Gozhora, Pisut Greetanukroh, Biobanco Gregorio Maranon, Tiziana Grossele, Shamiso Gwande, Tapiwa Gwaze, Tsitsi Gwenzi, James Hakim, Emmanuel Hakiza, Abdul Hamid Kaka, Ashley Harley, Mornay Isaacs, Richard Isabirye, Wilber Ishemunyoro, Tom Jacobs, Lungile Jafta, Nasir Jamil, Anita Janse Janse van Rensburg, Vinesh Jeaven, Maria José Mellado Peña, Gonzague Jourdain, Katabalwa Juliet, Thidarat Jumpimai, Raungwit Junkaew, Thidarat Jupimai, Winfred Kaahwa, Mildred Kabasonga, Olivia Kaboggoza, Rose Jacqueline Kadhuba, Ampika Kaewbundit, Kanyanee Kaewmamueng, Bosco Kafufu, Brenda Kakayi, Phakamas Kamboua, Suparat Kanjanavanit, Gladys Kasangaki, Naruporn Kasipong, Miriam Kasozi, Hajira Kataike, Chrispus Katemba, Nkata Kekane, Adeodata R. Kekitiinwa, Edridah Keminyeto, Woottichai Khamduang, Warunee Khamjakkaew, Jiraporn Khamkon, Sasipass Khannak, Orapin Khatngam, Tassawan Khayanchoomnoom, Busi Khumalo, Mirriam Khunene, Suwimon Khusuwan, Phionah Kibalama, Robinah Kibenge, Anthony Kirabira, Cissy M. Kityo, Lameck Kiyimba, Nigel Klein, Soraya Klinprung, Robin Kobbe, Olivia Kobusingye, Josephine Kobusungye, Areerat Kongponoi, Christoph Königs, Olivier Koole, Christelle Kouakam, Nitinart Krueduangkam, Namthip Kruenual, Nuananong Kunjaroenrut, Raymonds Kyambadde, Priscilla Kyobutungi, Flavia Kyomuhendo, Erinah Kyomukama, Reshma Lakha, Cleopatra Langa, Laddawan Laomanit, Emily Lebotsa, Prattana Leenasirimakul, Lawrence Lekku, Sarah Lensen, Valériane Leroy, Jin Li, Juthamas Limplertjareanwanich, Emma Little, Ezra Lutalo, Jose Luis Jimenez, Hermione Lyall, Candice MacDonald, Gladness Machache, Penelope Madlala, Tryphina Madonsela, Nomfundo Maduna, Joel Maena, Apicha Mahanontharit, Collin Makanga, Candice Makola, Shafic Makumbi, Lucille Malgraaf, Angelous Mamiane, Felicia Mantkowski, Wendy Mapfumo, Laura Marques, Agnes Mary Mugagga, Tshepiso Masienyane, Ruth Mathiba, Farai Matimba, Sajeeda Mawlana, Emmanuel Mayanja, Fatima Mayat, Ritah Mbabazi, Nokuthula Mbadaliga, Faith Mbasani, Kathleen McClaughlin, Helen McIlleron, Watchara Meethaisong, Patricia Mendez Garcia, Annet Miwanda, Carlota Miranda, Siphiwe Mkhize, Kgosimang Mmolawa, Fatima Mohamed, Tumelo Moloantoa, Maletsatsi Monametsi, Samuel Montero, Cecilia L. Moore, Rejoice Mosia, Columbus Moyo, Mumsy Mthethwa, Shepherd Mudzingwa, Tawona Mudzviti, Hilda Mujuru, Emmanuel Mujyambere, Trust Mukanganiki, Cynthia Mukisa Williams, Mark Mulder, Disan Mulima, Alice Mulindwa, Zivai Mupambireyi, Alba Murciano Cabeza, Herbert Murungi, Dorothy Murungu, Sandra Musarurwa, Victor Musiime, Alex V. Musiime, Maria Musisi, Philippa Musoke, Barbara Musoke Nakirya, Godfrey Musoro, Sharif Musumba, Sobia Mustafa, Shirley Mutsai, Phyllis Mwesigwa Rubondo, Mariam Naabalamba, Immaculate Nagawa, Allemah Naidoo, Shamim Nakabuye, Sarah Nakabuye, Sarah Nakalanzi, Justine Nalubwama, Annet Nalugo, Stella Nalusiba, Clementine Namajja, Sylvia Namanda, Paula Namayanja, Esther Nambi, Rachael Kikabi Namuddu, Stella Namukwaya, Florence Namuli, Josephine Namusanje, Rosemary Namwanje, Anusha Nanan-kanjee, Charity Nankunda, Joanita Nankya Baddokwaya, Maria Nannungi, Winnie Nansamba, Kesdao Nanthapisal, Juliet Nanyonjo, Sathaporn Na-Rajsima, Claire Nasaazi, Helena Nascimento, Eleni Nastouli, Wipaporn Natalie Songtaweesin, Kusum Nathoo, Ian Natuhurira, Rashidah Nazzinda, Thabisa Ncgaba, Milly Ndigendawani, Makhosonke Ndlovu, Georgina Nentsa, Chaiwat Ngampiyaskul, Ntombenhle Ngcobo, Nicole Ngo Giang Huong, Pia Ngwaru, Ruth Nhema, Emily Ninsiima, Gloria Ninsiima, Misheck Nkalo Phiri, Antoni Noguera Julian, Monica Nolan, Thornthun Noppakaorattanamanee, Muzamil Nsibuka Kisekka, Eniola Nsirim, Rashina Nundlal, Rosita Nunes, Lungile Nyantsa, Mandisa Nyati, Sean O'Riordan, Paul Ocitti Labeja, Denis Odoch, Rachel Oguntimehin, Martin Ojok, Geoffrey Onen, Wilma Orange, Pradthana Ounchanum, Benson Ouma, Andreia Padrao, Deborah Pako, Anna Parker, Malgorzata Pasko-Szcech, Reena Patel, Rukchanok Peongjakta, Turian Petpranee, Tasmin Phillips, Jackie Philps, Laura Picault, Sonja Pieterse, Helena Pinheiro, Supawadee Pongprapass, Anton Pozniak, Andrew Prendergast, Luis Prieto Tato, Patcharee Puangmalai, Thanyawee Puthanakit, Modiehi Rakgokong, Helena Ramos, Nastassja Ramsagar, Cornelius Rau, Yoann Riault, Pablo Rojo Conejo, Basiimwa Roy Clark, Eddie Rubanga, Baker Rubinga, Chutima Ruklao, Pattira Runarassamee, Chalermpong Saenjum, Chayakorn Saewtrakool, Yacine Saidi, Talia Sainz Costa, Chutima Saisaengjan, Rebecca Sakwa, Tatiana Sarfati, Noshalaza Sbisi, Dihedile Scheppers, Stephan Schultze-Strasser, Ulf Schulze-Sturm, Karen Scott, Janet Seeley, Robert Serunjogi, Leora Sewnarain, Subashinie Sidhoo, Mercy Shibemba, Delane Shingadia, Sheleika Singh, Wasna Sirirungsi, Sibongile Sithebe, Theresa Smit, Kurt Smith, Marlize Smuts, Moira Spyer, Worathip Sripaoraya, Ussanee Srirompotong, Warunee Srisuk, Mark Ssenyonga, Patamawadee Sudsaard, Praornsuda Sukrakanchana, Pathanee Tearsansern, Carla Teixeira, Kanchana Than-in-at, Thitiwat Thapwai, Yupawan Thaweesombat, Jutarat Thewsoongnoen, Rodolphe Thiébaut, Margaret Thomason, Laura Thrasyvoulou, Khanungnit Thungkham, Judith Tikabibamu, Gloria Tinago, Ketmookda Trairat, Gareth Tudor-Williams, Mercy Tukamushaba, Deogratiuos Tukwasibwe, Julius Tumusiime, Joana Tuna, Rebecca Turner, Arttasid Udomvised, Aasia Vadee, Hesti Van Huyssteen, Nadine Van Looy, Yvonne Vaughan-Gordon, Giulio Vecchia, Richard Vowden, Hylke Waalewijn, Rebecca Wampamba, Steve Welch, Ian Weller, Sibusisiwe Weza, Ian White, Kaja Widuch, Helen Wilkes, Sookpanee Wimonklang, Pacharaporn Yingyong, Zaam Zinda Nakawungu, and Peter Zuidewind
- Subjects
Adult ,Epidemiology ,Pyridones ,Anti-HIV Agents ,Immunology ,HIV Infections ,3-Ring ,Piperazines ,Heterocyclic Compounds ,Virology ,Oxazines ,Humans ,Protease Inhibitors ,Child ,Preschool ,Infant, Newborn ,Infant ,Bayes Theorem ,Viral Load ,Newborn ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Child, Preschool ,Heterocyclic Compounds, 3-Ring ,Treatment Outcome - Abstract
Contains fulltext : 283099.pdf (Publisher’s version ) (Open Access) BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial (10% margin) comparing dolutegravir-based ART with standard of care and comprises two cohorts (children weighing ≥14 kg and
- Published
- 2022
43. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
- Author
-
Anna Turkova, Hylke Waalewijn, Man K Chan, Pauline D J Bollen, Mutsa F Bwakura-Dangarembizi, Adeodata R Kekitiinwa, Mark F Cotton, Abbas Lugemwa, Ebrahim Variava, Grace Miriam Ahimbisibwe, Ussanee Srirompotong, Vivian Mumbiro, Pauline Amuge, Peter Zuidewind, Shabinah Ali, Cissy M Kityo, Moherndran Archary, Rashida A Ferrand, Avy Violari, Diana M Gibb, David M Burger, Deborah Ford, Angela Colbers, Amina Farhana Mehar (nee Abdulla), Pattamukkil Abraham, Elaine Abrams, Judith Acero, Gerald Muzorah Agaba, Grace Ahimbisibwe, Barbara Ainebyoona, Winnie Akobye, Yasmeen Akhalwaya, Nazim Akoojee, Shabinah S. Ali, Catherine Andrea, Maria Angeles Muñoz Fernandez, Rogers Ankunda, Diana Antonia Rutebarika, Suvaporn Anugulruengkitt, Tsitsi Apollo, Ronelle Arendze, Juliet Ategeka, Eunice Atim, Lorna Atwine, Abdel Babiker, Sarah Babirye, Enock Babu, Edward Bagirigomwa, Angella Baita, David Balamusani, Patsy Baliram, David Baliruno, Colin Ball, Henry Balwa, Alasdair Bamford, Srini Bandi, Dominique Barker, Linda Barlow-Mosha, Dickson Bbuye, Shazia Begum, Osee Behuhuma, Sarah Bernays, Rogers Besigye, Maria Bester, Joyline Bhiri, Davide Bilardi, Kristien Bird, Pauline Bollen, Chiara Borg, Anne-Marie Borges Da Silva, Jackie Brown, Elena Bruno, Torsak Bunupuradah, David Burger, Nomzamo Buthelezi, Mutsa Bwakura-Dangarembizi, Africanus Byaruhanga, Joanna Calvert, Petronelle Casey, Haseena Cassim, Sphiwee Cebekhulu, Sanuphong Chailert, Suwalai Chalermpantmetagul, Wanna Chamjamrat, Man Chan, Precious Chandiwana, Thannapat Chankun, Sararut Chanthaburanun, Nuttawut Chanto, Ennie Chidziva, Minenhle Chikowore, Joy Chimanzi, Dujrudee Chinwong, Stuart Chitongo, Moses Chitsamatanga, Joshua Choga, Duangrat Chutima, Polly Clayden, Alexandra Coelho, Alexandra Compagnucci, Ana Constança Mendes, Magda Conway, Mark F. Cotton, Jane Crawley, Tim R. Cressey, Jacky Crisp, Ana Cristina Matos, Sumaya Dadan, Jacqui Daglish, Siva Danaviah, Tseleng Daniel, Anita De Rossi, Sukanda Denjanta, Els Dobbels, Maria Dowie, Prosper Dube, Benedictor Dube, Nimisha Dudakia, Alice Elwana, Cristina Epalza, David Eram, Juan Erasmus, Peter Erim, Luis Escosa Garcia, Zaakirah Essack, Carolina Estepa, Monica Etima, Alexandre Fernandes, Maite Fernandez, Felicity Fitzgerald, Jacquie Flynn, Claudia Fortuny Guasch, Caroline Foster, George Fourie, Yolandie Fourie, Sophie Foxall, Derusha Frank, Kate Gandhi, India Garcia, Kathleen Gartner, Joshua Gasa, Gugu Gasa, Carlo Giaquinto, Diana M. Gibb, Coral Gomez Rico, Daniel Gomez-Pena, Secrecy Gondo, Anna Goodman, Maria Gorreti Nakalema, Winnie Gozhora, Pisut Greetanukroh, Biobanco Gregorio Maranon, Tiziana Grossele, Shamiso Gwande, Tapiwa Gwaze, Tsitsi Gwenzi, James Hakim, Emmanuel Hakiza, Abdul Hamid Kaka, Ashley Harley, Mornay Isaacs, Richard Isabirye, Wilber Ishemunyoro, Tom Jacobs, Lungile Jafta, Nasir Jamil, Anita Janse Janse van Rensburg, Vinesh Jeaven, Maria José Mellado Peña, Gonzague Jourdain, Katabalwa Juliet, Thidarat Jumpimai, Raungwit Junkaew, Thidarat Jupimai, Winfred Kaahwa, Mildred Kabasonga, Olivia Kaboggoza, Rose Jacqueline Kadhuba, Ampika Kaewbundit, Kanyanee Kaewmamueng, Bosco Kafufu, Brenda Kakayi, Phakamas Kamboua, Suparat Kanjanavanit, Gladys Kasangaki, Naruporn Kasipong, Miriam Kasozi, Hajira Kataike, Chrispus Katemba, Elizabeth Kaudha, Nkata Kekane, Adeodata R. Kekitiinwa, Edridah Keminyeto, Woottichai Khamduang, Warunee Khamjakkaew, Jiraporn Khamkon, Sasipass Khannak, Orapin Khatngam, Tassawan Khayanchoomnoom, Busi Khumalo, Mirriam Khunene, Suwimon Khusuwan, Phionah Kibalama, Robinah Kibenge, Anthony Kirabira, Cissy M. Kityo, Lameck Kiyimba, Nigel Klein, Soraya Klinprung, Robin Kobbe, Olivia Kobusingye, Josephine Kobusungye, Areerat Kongponoi, Christoph Königs, Olivier Koole, Christelle Kouakam, Nitinart Krueduangkam, Namthip Kruenual, Nuananong Kunjaroenrut, Raymonds Kyambadde, Priscilla Kyobutungi, Flavia Kyomuhendo, Erinah Kyomukama, Reshma Lakha, Cleopatra Langa, Laddawan Laomanit, Emily Lebotsa, Prattana Leenasirimakul, Lawrence Lekku, Sarah Lensen, Valériane Leroy, Jin Li, Afaaf Liberty, Juthamas Limplertjareanwanich, Emma Little, Ezra Lutalo, Jose Luis Jimenez, Hermione Lyall, Candice MacDonald, Gladness Machache, Penelope Madlala, Tryphina Madonsela, Nomfundo Maduna, Joel Maena, Apicha Mahanontharit, Collin Makanga, Candice Makola, Shafic Makumbi, Lucille Malgraaf, Angelous Mamiane, Felicia Mantkowski, Wendy Mapfumo, Laura Marques, Agnes Mary Mugagga, Lindiwe Maseko, Tshepiso Masienyane, Ruth Mathiba, Farai Matimba, Sajeeda Mawlana, Emmanuel Mayanja, Fatima Mayat, Ritah Mbabazi, Nokuthula Mbadaliga, Faith Mbasani, Kathleen McClaughlin, Helen McIlleron, Watchara Meethaisong, Patricia Mendez Garcia, Annet Miwanda, Carlota Miranda, Siphiwe Mkhize, Kgosimang Mmolawa, Rosie Mngqibisa, Fatima Mohamed, Tumelo Moloantoa, Maletsatsi Monametsi, Samuel Montero, Cecilia L. Moore, Rejoice Mosia, Columbus Moyo, Mumsy Mthethwa, Shepherd Mudzingwa, Tawona Mudzviti, Hilda Mujuru, Emmanuel Mujyambere, Trust Mukanganiki, Cynthia Mukisa Williams, Mark Mulder, Disan Mulima, Alice Mulindwa, Zivai Mupambireyi, Alba Murciano Cabeza, Herbert Murungi, Dorothy Murungu, Sandra Musarurwa, Victor Musiime, Alex V. Musiime, Maria Musisi, Philippa Musoke, Barbara Musoke Nakirya, Godfrey Musoro, Sharif Musumba, Sobia Mustafa, Shirley Mutsai, Phyllis Mwesigwa Rubondo, Mariam Naabalamba, Immaculate Nagawa, Allemah Naidoo, Shamim Nakabuye, Sarah Nakabuye, Sarah Nakalanzi, Justine Nalubwama, Annet Nalugo, Stella Nalusiba, Clementine Namajja, Sylvia Namanda, Paula Namayanja, Esther Nambi, Rachael Kikabi Namuddu, Stella Namukwaya, Florence Namuli, Josephine Namusanje, Rosemary Namwanje, Anusha Nanan-kanjee, Annet Nanduudu, Charity Nankunda, Joanita Nankya Baddokwaya, Maria Nannungi, Winnie Nansamba, Kesdao Nanthapisal, Juliet Nanyonjo, Sathaporn Na-Rajsima, Claire Nasaazi, Helena Nascimento, Eleni Nastouli, Wipaporn Natalie Songtaweesin, Kusum Nathoo, Ian Natuhurira, Rashidah Nazzinda, Thabisa Ncgaba, Milly Ndigendawani, Makhosonke Ndlovu, Georgina Nentsa, Chaiwat Ngampiyaskul, Ntombenhle Ngcobo, Nicole Ngo Giang Huong, Pia Ngwaru, Ruth Nhema, Emily Ninsiima, Gloria Ninsiima, Misheck Nkalo Phiri, Antoni Noguera Julian, Monica Nolan, Thornthun Noppakaorattanamanee, Muzamil Nsibuka Kisekka, Eniola Nsirim, Rashina Nundlal, Rosita Nunes, Lungile Nyantsa, Mandisa Nyati, Sean O'Riordan, Paul Ocitti Labeja, Denis Odoch, Rachel Oguntimehin, Martin Ojok, Geoffrey Onen, Wilma Orange, Pradthana Ounchanum, Benson Ouma, Andreia Padrao, Deborah Pako, Anna Parker, Malgorzata Pasko-Szcech, Reena Patel, Rukchanok Peongjakta, Turian Petpranee, Tasmin Phillips, Jackie Philps, Laura Picault, Sonja Pieterse, Helena Pinheiro, Supawadee Pongprapass, Anton Pozniak, Andrew Prendergast, Luis Prieto Tato, Patcharee Puangmalai, Thanyawee Puthanakit, Modiehi Rakgokong, Helena Ramos, Nastassja Ramsagar, Cornelius Rau, Yoann Riault, Pablo Rojo Conejo, Basiimwa Roy Clark, Eddie Rubanga, Baker Rubinga, Chutima Ruklao, Pattira Runarassamee, Chalermpong Saenjum, Chayakorn Saewtrakool, Yacine Saidi, Talia Sainz Costa, Chutima Saisaengjan, Rebecca Sakwa, Tatiana Sarfati, Noshalaza Sbisi, Dihedile Scheppers, Stephan Schultze-Strasser, Ulf Schulze-Sturm, Karen Scott, Janet Seeley, Robert Serunjogi, Leora Sewnarain, Clare Shakeshaft, Subashinie Sidhoo, Mercy Shibemba, Delane Shingadia, Sheleika Singh, Wasna Sirirungsi, Sibongile Sithebe, Theresa Smit, Kurt Smith, Marlize Smuts, Moira Spyer, Worathip Sripaoraya, Warunee Srisuk, Mark Ssenyonga, Patamawadee Sudsaard, Praornsuda Sukrakanchana, Pathanee Tearsansern, Carla Teixeira, Kanchana Than-in-at, Thitiwat Thapwai, Yupawan Thaweesombat, Jutarat Thewsoongnoen, Rodolphe Thiébaut, Margaret Thomason, Laura Thrasyvoulou, Khanungnit Thungkham, Judith Tikabibamu, Gloria Tinago, Ketmookda Trairat, Gareth Tudor-Williams, Mercy Tukamushaba, Deogratiuos Tukwasibwe, Julius Tumusiime, Joana Tuna, Rebecca Turner, Arttasid Udomvised, Aasia Vadee, Hesti Van Huyssteen, Nadine Van Looy, Yvonne Vaughan-Gordon, Giulio Vecchia, Richard Vowden, Rebecca Wampamba, Steve Welch, Ian Weller, Sibusisiwe Weza, Ellen White, Ian White, Kaja Widuch, Helen Wilkes, Sookpanee Wimonklang, Ben Wynne, Pacharaporn Yingyong, and Zaam Zinda Nakawungu
- Subjects
Male ,Adolescent ,Pyridones ,Epidemiology ,Immunology ,Infant ,HIV Infections ,3-Ring ,Piperazines ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Infectious Diseases ,Child ,Child, Preschool ,Female ,Heterocyclic Compounds, 3-Ring ,Humans ,Oxazines ,Rifampin ,Uganda ,HIV-1 ,Tuberculosis ,Heterocyclic Compounds ,Virology ,Preschool - Abstract
Contains fulltext : 282959.pdf (Publisher’s version ) (Open Access) BACKGROUND: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. METHODS: We nested a two-period, fixed-order pharmacokinetic substudy within the open-label, multicentre, randomised, controlled, non-inferiority ODYSSEY trial at research centres in South Africa, Uganda, and Zimbabwe. Children (aged 4 weeks to
- Published
- 2022
44. Citizen Science Approach to Home Radon Testing, Environmental Health Literacy and Efficacy
- Author
-
Stanifer, Stacy, primary, Hoover, Anna Goodman, additional, Rademacher, Kathy, additional, Rayens, Mary Kay, additional, Haneberg, William, additional, and Hahn, Ellen J., additional
- Published
- 2022
- Full Text
- View/download PDF
45. Classifying Community Organizational Health Communication Networks: Local Health Department Recognition of Public Information-Sharing Partners Across Sectors
- Author
-
Pierre Dominique Zephyr and Anna Goodman Hoover
- Subjects
medicine.medical_specialty ,Local Government ,Information Dissemination ,business.industry ,Health Policy ,Public health ,Information sharing ,Public Health, Environmental and Occupational Health ,Health Promotion ,Public relations ,Community Networks ,Metropolitan area ,Health Communication ,medicine ,Humans ,Organizational communication ,Public Health ,business ,Public Health Administration ,Health communication ,Social network analysis ,Health department ,Mass media - Abstract
OBJECTIVE Local health departments (LHDs) operate within complex, multisectoral organizational communication networks. Network composition may affect priorities, processes, and the reach of health information to key stakeholders. This study seeks to elucidate variation in local network structures to examine how different constellations may affect information sharing across audiences. DESIGN This study analyzes data from a 2016 US survey of 491 metropolitan LHDs and 556 nonmetropolitan LHDs. Researchers first conducted social network analysis of network density, defined as the total number of potential organizations contributing to a jurisdiction's health communication activities. Researchers then conducted logistic regression to compare the relationship between network density and reported health communication activities targeting 3 specific audiences: policy makers, lay publics, and mass media. RESULTS Three network types emerged on the basis of the number of organizations that contribute to health communication activities, with low-density Minimal networks more common in nonmetropolitan jurisdictions and higher-density Expanded and Robust networks more common in metropolitan jurisdictions. LHDs in Minimal networks were significantly less likely to communicate with policy makers, lay publics, and mass media than their counterparts in higher-density networks (P < .05). CONCLUSIONS LHDs are embedded in organizational communication networks that vary in both the number of communication partners and the types of audiences reached. Examining their own local organizational communication networks may provide insights into LHDs that wish to improve the effectiveness of public health messaging. By adding organizational communication partners and reaching new audiences, LHDs in Minimal networks can expand the reach of messages designed to help policy makers, communities, and individuals promote health and prevent disease.
- Published
- 2020
46. Experience of a novel community testing programme for COVID-19 in London: Lessons learnt
- Author
-
Cindy Marudamuthu, Tommy Rampling, Anna Goodman, Francesca Siracusa, Fenella Wrigley, Gabriel Wallis, Michael Blank, Tumena Corrah, Ashley Whittington, Javier Sanchez, Sarah Logan, Padmasayee Papineni, Victoria Parris, Laurence John, Helena Painter, Bhanu Williams, Kelcy Salinas, Cherifer Mamuyac, Gurjinder Sandhu, Alastair McGregor, and Deborah Miller
- Subjects
Male ,Program evaluation ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Isolation (health care) ,Cross-sectional study ,Pneumonia, Viral ,Psychological intervention ,Audit ,030204 cardiovascular system & hematology ,03 medical and health sciences ,COVID-19 Testing ,0302 clinical medicine ,London ,Pandemic ,medicine ,Humans ,Mass Screening ,Community Health Services ,030212 general & internal medicine ,Program Development ,Pandemics ,Clinical Laboratory Techniques ,business.industry ,COVID-19 rapid report ,Public health ,COVID-19 ,General Medicine ,Cross-Sectional Studies ,England ,Family medicine ,Patient Compliance ,Female ,Public Health ,Coronavirus Infections ,business ,Program Evaluation - Abstract
We describe the London community testing programme developed for COVID-19, audit its effectiveness and report patient acceptability and patient adherence to isolation guidance, based upon a survey conducted with participants. Any patients meeting the Public Health England (PHE) case definition for COVID-19 who did not require hospital admission were eligible for community testing. 2,053 patients with suspected COVID-19 were tested in the community between January and March 2020. Of those tested, 75 (3.6%) were positive. 88% of patients that completed a patient survey felt safe and 82% agreed that community testing was preferable to hospital admission. 97% were able to remain within their own home during the isolation period but just 41% were able to reliably isolate from other members of their household. The London community testing programme allowed widespread testing for COVID-19 while minimising patient transport, hospital admissions and staff exposures. Community testing was acceptable to patients and preferable to admission to hospital. Patients were able to reliably isolate in their home but not from household contacts. The authors believe in the importance, feasibility and acceptability of community testing for COVID-19 as a part of a package of interventions to mitigate a second wave of infection.
- Published
- 2020
47. Research for city practice
- Author
-
Marcus Grant, Lindsay McCunn, Sohail Ahmad, Anna Goodman, Felix Creutzig, James Woodcock, Marko Tainio, Tisha Holmes, David Eisenman, Louise Warwick-Booth, Susan Coan, Anne-Marie Bagnall, Chris Neale, Peter Aspinall, Jenny Roe, Sara Tilley, Panagiotis Mavros, Steve Cinderby, Richard Coyne, Neil Thin, Catherine Ward Thompson, Maria Anna Gardener, Fabiano Lemes de Oliveira, Flora M. Vieira Zamora, Marita Kloseck, Deborah A. Fitzsimmons, Aleksandra Zecevic, and Patrick Fleming
- Subjects
Urban Studies ,Public Health, Environmental and Occupational Health - Published
- 2020
48. Treatment of chronic or relapsing COVID-19 in immunodeficiency
- Author
-
Adrian M Shields, Sujoy Khan, Aisha Patel, Alex G. Richter, David M. Lowe, Iman AbdulKhaliq, Alexander Robbins, Jonathan Underwood, Helen Baxendale, Stephen Jolles, Megan Jenkins, Matthew Buckland, Michael Hunter, Ed Moran, Michael Brown, William H. Bermingham, Li-An K. Brown, Hannah Jarvis, Thomas Simpson, Anna Goodman, Sinisa Savic, and Surendra Karanam
- Subjects
Adult ,Male ,medicine.medical_specialty ,Recombinant Fusion Proteins ,Immunology ,Population ,X-linked agammaglobulinemia ,remdesivir ,Disease ,Antiviral Agents ,Article ,Recurrence ,Internal medicine ,medicine ,Immunology and Allergy ,Humans ,Lymphocyte Count ,Treatment Failure ,education ,Immunodeficiency ,COVID-19 Serotherapy ,Aged ,Aged, 80 and over ,education.field_of_study ,B-Lymphocytes ,Alanine ,biology ,business.industry ,SARS-CoV-2 ,Common variable immunodeficiency ,C-reactive protein ,Immunization, Passive ,Immunologic Deficiency Syndromes ,Antibodies, Monoclonal ,COVID-19 ,therapeutic monoclonal ,Middle Aged ,medicine.disease ,Adenosine Monophosphate ,Cohort ,Chronic Disease ,biology.protein ,Female ,Antibody ,business ,immunodeficiency - Abstract
Patients with some types of immunodeficiency can experience chronic or relapsing infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This leads to morbidity and mortality, infection control challenges, and the risk of evolution of novel viral variants. The optimal treatment for chronic coronavirus disease 2019 (COVID-19) is unknown.Our aim was to characterize a cohort of patients with chronic or relapsing COVID-19 disease and record treatment response.We conducted a UK physician survey to collect data on underlying diagnosis and demographics, clinical features, and treatment response of immunodeficient patients with chronic (lasting ≥21 days) or relapsing (≥2 episodes) of COVID-19.We identified 31 patients (median age 49 years). Their underlying immunodeficiency was most commonly characterized by antibody deficiency with absent or profoundly reduced peripheral B-cell levels; prior anti-CD20 therapy, and X-linked agammaglobulinemia. Their clinical features of COVID-19 were similar to those of the general population, but their median duration of symptomatic disease was 64 days (maximum 300 days) and individual patients experienced up to 5 episodes of illness. Remdesivir monotherapy (including when given for prolonged courses of ≤20 days) was associated with sustained viral clearance in 7 of 23 clinical episodes (30.4%), whereas the combination of remdesivir with convalescent plasma or anti-SARS-CoV-2 mAbs resulted in viral clearance in 13 of 14 episodes (92.8%). Patients receiving no therapy did not clear SARS-CoV-2.COVID-19 can present as a chronic or relapsing disease in patients with antibody deficiency. Remdesivir monotherapy is frequently associated with treatment failure, but the combination of remdesivir with antibody-based therapeutics holds promise.
- Published
- 2021
49. Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity
- Author
-
Sangita Agarwal, Jo Salkeld, Hanna Nguyen, and Anna Goodman
- Subjects
medicine.medical_specialty ,media_common.quotation_subject ,medicine.medical_treatment ,Remdesivir ,Case Reports and Series ,Disease ,Infectious and parasitic diseases ,RC109-216 ,Pneumocystis pneumonia ,Immune system ,Agammaglobulinemia ,Internal medicine ,medicine ,media_common ,Anakinra ,biology ,business.industry ,Convalescence ,COVID-19 ,Immunosuppression ,medicine.disease ,REGN-COV2 ,Infectious Diseases ,Cohort ,SARS-CoV2 ,biology.protein ,Antibody ,business ,medicine.drug - Abstract
Background The role of antibodies in coronavirus disease 2019 (COVID-19) in patients with X-linked agammaglobulinaemia (XLA) has yet to be characterised and clinical courses observed in this cohort of patients have been heterogeneous. Whilst some exhibit spontaneous recovery, others have experienced a more protracted disease length. Previous reports have described successful use of convalescent plasma, however there is a paucity of information around the use of the REGN-COV2 antibody cocktail in these patients. Case report A patient with XLA was admitted to hospital with COVID-19 and remained persistently symptomatic with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) swab positivity despite treatment with Remdesivir and dexamethasone. Attempts at modulating the immune response with anakinra were unsuccessful. Consent for compassionate use of REGN-COV2 was obtained with administration taking place on day 87 of his illness. This was followed by a period of convalescence and SARS-CoV-2 nasopharyngeal swab negativity. As a consequence of prolonged immunosuppression, the patient developed pneumocystis pneumonia. Conclusion This case highlights the role of antibodies in clearing SARS-CoV-2 in a hypogammaglobulinaemic host and demonstrates the consequences of prolonged immunosuppression and delayed treatment. We propose that this may be of particular significance given the capacity of SARS-CoV-2 to develop advantageous mutations in a chronically infected host.
- Published
- 2021
50. The Propensity to Cycle Tool: An open source online system for sustainable transport planning.
- Author
-
Robin Lovelace, Anna Goodman, Rachel Aldred, Nikolai Berkoff, Ali Abbas, and James Woodcock
- Published
- 2015
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.